GenXys Health Care Systems

REFERENCES USED IN ALGORITHMS FOR THE TREATMENT OF PERSONS WITH DEPRESSION

1. American Psychological Association: Clinical practice guideline for the treatment of depression across three age cohorts. 2019.

2. Quality AfHRa: Second-Generation Antidepressants in the Pharmacologic Treatment of Adult Depression: An Update of the 2007 Comparative Effectiveness Review. In: Effective Health Care Program. Rockville, MD: AHRQ; 2019.

3. Kennedy SH, Lam RW, McIntyre RS, Tourjman SV, Bhat V, Blier P, Hasnain M, Jollant F, Levitt AJ, MacQueen GM et al: Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 3. Pharmacological Treatments. Can J Psychiatry 2016, 61(9):540-560.

4. Wagner G, Schultes MT, Titscher V, Teufer B, Klerings I, Gartlehner G: Efficacy and safety of levomilnacipran, vilazodone and vortioxetine compared with other second-generation antidepressants for major depressive disorder in adults: A systematic review and network meta-analysis. J Affect Disord 2018, 228:1-12.

5. Bauer M, Bschor T, Pfennig A, Whybrow PC, Angst J, Versiani M, Moller HJ: World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders in Primary Care. World J Biol Psychiatry 2007, 8(2):67-104.

6. Wenzel-Seifert K, Wittmann M, Haen E: QTc prolongation by psychotropic drugs and the risk of Torsade de Pointes. Dtsch Arztebl Int 2011, 108(41):687-693.

7. Henssler J, Heinz A, Brandt L, Bschor T: Antidepressant Withdrawal and Rebound Phenomena. Dtsch Arztebl Int 2019, 116(20):355-361.

8. National Institute for Health and Care Excellence: Guideline on the Treatment and Managment of Depression in Adults [NICE Guideline 90]. 2009.

9. American Psychiatric Association: Practice Guideline for the Treatment of Patients with Major Depressive Disorder. In: APA Guideline. Third Edition edn: American Psychiatric Association; 2010.

10. Guidelines B: Major Depressive Issues in Adults: Appendix D. 2013.

11. VA/DoD The Management of Major Depressive Disorder Working Group: VA/DoD Clinical Practice Guideline for the Management of Major Depressive Disorder. Online: Department of Veterans Affairs, Department of Defense; 2016.

12. Faquih AE, Memon RI, Hafeez H, Zeshan M, Naveed S: A Review of Novel Antidepressants: A Guide for Clinicians. Cureus 2019, 11(3):e4185.

13. Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, Leucht S, Ruhe HG, Turner EH, Higgins JPT et al: Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet 2018, 391(10128):1357-1366.

14. McIntyre R, Gommoll C, Chen C, Ruth A: The efficacy of levomilnacipran ER across symptoms of major depressive disorder: a post hoc analysis of 5 randomized, double-blind, placebo-controlled trials. CNS spectrums 2016, -1:1-8.

15. McIntyre RS: The role of new antidepressants in clinical practice in Canada: a brief review of vortioxetine, levomilnacipran ER, and vilazodone. Neuropsychiatr Dis Treat 2017, 13:2913-2919.

16. Serretti A: The Present and Future of Precision Medicine in Psychiatry: Focus on Clinical Psychopharmacology of Antidepressants. Clinical Psychopharmacology and Neuroscience 2018, 16:1-6.

17. Malhi GS, Bassett D, Boyce P, Bryant R, Fitzgerald PB, Fritz K, Hopwood M, Lyndon B, Mulder R, Murray G et al: Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders. Aust N Z J Psychiatry 2015, 49(12):1087-1206.

18. Fasipe OJ: The emergence of new antidepressants for clinical use: Agomelatine paradox versus other novel agents. IBRO Rep 2019, 6:95-110.

19. Wang SM, Han C, Lee SJ, Patkar AA, Masand PS, Pae CU: Vilazodone for the Treatment of Depression: An Update. Chonnam Med J 2016, 52(2):91-100.

20. Mathews M, Gommoll C, Chen D, Nunez R, Khan A: Efficacy and safety of vilazodone 20 and 40 mg in major depressive disorder: a randomized, double-blind, placebo-controlled trial. Int Clin Psychopharmacol 2015, 30(2):67-74.

21. Koesters M, Ostuzzi G, Guaiana G, Breilmann J, Barbui C: Vortioxetine for depression in adults. Cochrane Database Syst Rev 2017, 7:Cd011520.

22. Long JD: Vortioxetine for Depression in Adults. Issues in Mental Health Nursing 2019, 40(9):819-820.

23. Young AH, Evitt L, Brignone M, Diamand F, Atsou K, Campbell R, Cure S, Danchenko N: Cost-utility evaluation of vortioxetine in patients with Major Depressive Disorder experiencing inadequate response to alternative antidepressants in the United Kingdom. J Affect Disord 2017, 218:291-298.

24. Thase ME, Danchenko N, Brignone M, Florea I, Diamand F, Jacobsen PL, Vieta E: Comparative evaluation of vortioxetine as a switch therapy in patients with major depressive disorder. European Neuropsychopharmacology 2017, 27(8):773-781.

25. Cleare A, Pariante C, Young A, Anderson I, Christmas D, Cowen P, Dickens C, Ferrier IN, Geddes J, Gilbody S et al: Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2008 British Association for Psychopharmacology guidelines (BAP). Journal of psychopharmacology (Oxford, England) 2015, 29.

26. Lam RW, Kennedy SH, Grigoriadis S, McIntyre RS, Milev R, Ramasubbu R, Parikh SV, Patten SB, Ravindran AV, Canadian Network for M et al: Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy. J Affect Disord 2009, 117 Suppl 1:S26-43.

27. Papakostas G, Fava M: A Metaanalysis of Clinical Trials Comparing Moclobemide with Selective Serotonin Reuptake Inhibitors for the Treatment of Major Depressive Disorder. Canadian journal of psychiatry Revue canadienne de psychiatrie 2006, 51:783-790.

28. Lotufo-Neto F, Trivedi M, Thase ME: Meta-analysis of the reversible inhibitors of monoamine oxidase type A moclobemide and brofaromine for the treatment of depression. Neuropsychopharmacology 1999, 20(3):226-247.

29. Linde K, Kriston L, Rucker G, Jamil S, Schumann I, Meissner K, Sigterman K, Schneider A: Efficacy and acceptability of pharmacological treatments for depressive disorders in primary care: systematic review and network meta-analysis. Ann Fam Med 2015, 13(1):69-79.

30. Cristancho MA, Thase ME: Critical appraisal of selegiline transdermal system for major depressive disorder. Expert Opin Drug Deliv 2016, 13(5):659-665.

31. National Institute for Health and Care Excellence: Depression in adults: recognition and management (summary) [NICE Guideline 90]. In: NICE Clinical Guideline. 2009 (2019 update).

32. Kasper S, Pail G: Milnacipran: a unique antidepressant? Neuropsychiatr Dis Treat 2010, 6:23-31.

33. Papakostas GI, Fava M: A meta-analysis of clinical trials comparing milnacipran, a serotonin--norepinephrine reuptake inhibitor, with a selective serotonin reuptake inhibitor for the treatment of major depressive disorder. Eur Neuropsychopharmacol 2007, 17(1):32-36.

34. Nakagawa A, Watanabe N, Omori IM, Barbui C, Cipriani A, McGuire H, Churchill R, Furukawa TA: Milnacipran versus other antidepressive agents for depression. Cochrane Database Syst Rev 2009(3):CD006529-CD006529.

35. Important Safety Information Regarding the Discontinuation of Sales of Nefazodone in Canada [https://www.healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2003/14224a-eng.php]

36. Bennabi D, Charpeaud T, Yrondi A, Genty JB, Destouches S, Lancrenon S, Alaili N, Bellivier F, Bougerol T, Camus V et al: Clinical guidelines for the management of treatment-resistant depression: French recommendations from experts, the French Association for Biological Psychiatry and Neuropsychopharmacology and the fondation FondaMental. BMC Psychiatry 2019, 19(1):262.

37. Zhou X, Ravindran AV, Qin B, Del Giovane C, Li Q, Bauer M, Liu Y, Fang Y, da Silva T, Zhang Y et al: Comparative efficacy, acceptability, and tolerability of augmentation agents in treatment-resistant depression: systematic review and network meta-analysis. J Clin Psychiatry 2015, 76(4):e487-498.

38. Strawbridge R, Carter B, Marwood L, Bandelow B, Tsapekos D, Nikolova VL, Taylor R, Mantingh T, de Angel V, Patrick F et al: Augmentation therapies for treatment-resistant depression: systematic review and meta-analysis. Br J Psychiatry 2019, 214(1):42-51.

39. Zhou X, Keitner GI, Qin B, Ravindran AV, Bauer M, Del Giovane C, Zhao J, Liu Y, Fang Y, Zhang Y et al: Atypical Antipsychotic Augmentation for Treatment-Resistant Depression: A Systematic Review and Network Meta-Analysis. Int J Neuropsychopharmacol 2015, 18(11):pyv060.

40. Komossa K, Depping AM, Gaudchau A, Kissling W, Leucht S: Second-generation antipsychotics for major depressive disorder and dysthymia. Cochrane Database Syst Rev 2010(12):Cd008121.

41. Spielmans GI, Berman MI, Linardatos E, Rosenlicht NZ, Perry A, Tsai AC: Adjunctive atypical antipsychotic treatment for major depressive disorder: a meta-analysis of depression, quality of life, and safety outcomes. PLoS Med 2013, 10(3):e1001403.

42. Citrome L: Adjunctive aripiprazole, olanzapine, or quetiapine for major depressive disorder: an analysis of number needed to treat, number needed to harm, and likelihood to be helped or harmed. Postgrad Med 2010, 122(4):39-48.

43. Nelson JC, Papakostas GI: Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am J Psychiatry 2009, 166(9):980-991.

44. Mohamed S, Johnson GR, Chen P, Hicks PB, Davis LL, Yoon J, Gleason TC, Vertrees JE, Weingart K, Tal I et al: Effect of Antidepressant Switching vs Augmentation on Remission Among Patients With Major Depressive Disorder Unresponsive to Antidepressant Treatment: The VAST-D Randomized Clinical Trial. Jama 2017, 318(2):132-145.

45. Hobart M, Skuban A, Zhang P, Josiassen MK, Hefting N, Augustine C, Brewer C, Sanchez R, McQuade RD: Efficacy and safety of flexibly dosed brexpiprazole for the adjunctive treatment of major depressive disorder: a randomized, active-referenced, placebo-controlled study. Curr Med Res Opin 2018, 34(4):633-642.

46. Papadimitropoulou K, Vossen C, Karabis A, Donatti C, Kubitz N: Comparative efficacy and tolerability of pharmacological and somatic interventions in adult patients with treatment-resistant depression: a systematic review and network meta-analysis. Curr Med Res Opin 2017, 33(4):701-711.

47. Bauer M, Dell'osso L, Kasper S, Pitchot W, Dencker Vansvik E, Kohler J, Jorgensen L, Montgomery SA: Extended-release quetiapine fumarate (quetiapine XR) monotherapy and quetiapine XR or lithium as add-on to antidepressants in patients with treatment-resistant major depressive disorder. Journal of affective disorders 2013, 151(1):209-219.

48. Fang Y, Yuan C, Xu Y, Chen J, Wu Z, Cao L, Yi Z, Hong W, Wang Y, Jiang K et al: A pilot study of the efficacy and safety of paroxetine augmented with risperidone, valproate, buspirone, trazodone, or thyroid hormone in adult Chinese patients with treatment-resistant major depression. J Clin Psychopharmacol 2011, 31(5):638-642.

49. Edwards SJ, Hamilton V, Nherera L, Trevor N: Lithium or an atypical antipsychotic drug in the management of treatment-resistant depression: a systematic review and economic evaluation. Health Technol Assess 2013, 17(54):1-190.

50. Turner P, Kantaria R, Young AH: A systematic review and meta-analysis of the evidence base for add-on treatment for patients with major depressive disorder who have not responded to antidepressant treatment: a European perspective. J Psychopharmacol 2014, 28(2):85-98.

51. Yoshimura R, Hori H, Umene-Nakano W, Ikenouchi-Sugita A, Katsuki A, Atake K, Nakamura J: Comparison of lithium, aripiprazole and olanzapine as augmentation to paroxetine for inpatients with major depressive disorder. Ther Adv Psychopharmacol 2014, 4(3):123-129.

52. Cheon EJ, Lee KH, Park YW, Lee JH, Koo BH, Lee SJ, Sung HM: Comparison of the Efficacy and Safety of Aripiprazole Versus Bupropion Augmentation in Patients With Major Depressive Disorder Unresponsive to

Selective Serotonin Reuptake Inhibitors: A Randomized, Prospective, Open-Label Study. J Clin Psychopharmacol 2017, 37(2):193-199.

53. Doree JP, Des Rosiers J, Lew V, Gendron A, Elie R, Stip E, Tourjman SV: Quetiapine augmentation of treatment-resistant depression: a comparison with lithium. Curr Med Res Opin 2007, 23(2):333-341.

54. Barbee JG, Conrad EJ, Jamhour NJ: The effectiveness of olanzapine, risperidone, quetiapine, and ziprasidone as augmentation agents in treatment-resistant major depressive disorder. J Clin Psychiatry 2004, 65(7):975-981.

55. Nierenberg AA, Fava M, Trivedi MH, Wisniewski SR, Thase ME, McGrath PJ, Alpert JE, Warden D, Luther JF, Niederehe G et al: A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report. Am J Psychiatry 2006, 163(9):1519-1530; quiz 1665.

56. Joffe RT, Singer W, Levitt AJ, MacDonald C: A placebo-controlled comparison of lithium and triiodothyronine augmentation of tricyclic antidepressants in unipolar refractory depression. Arch Gen Psychiatry 1993, 50(5):387-393.

57. Joffe RT, Sokolov ST, Levitt AJ: Lithium and triiodothyronine augmentation of antidepressants. Can J Psychiatry 2006, 51(12):791-793.

58. Schindler F, Anghelescu IG: Lithium versus lamotrigine augmentation in treatment resistant unipolar depression: a randomized, open-label study. Int Clin Psychopharmacol 2007, 22(3):179-182.

59. Trivedi MH, Fava M, Wisniewski SR, Thase ME, Quitkin F, Warden D, Ritz L, Nierenberg AA, Lebowitz BD, Biggs MM et al: Medication augmentation after the failure of SSRIs for depression. N Engl J Med 2006, 354(12):1243-1252.

60. Wang HR, Woo YS, Ahn HS, Ahn IM, Kim HJ, Bahk WM: Can Atypical Antipsychotic Augmentation Reduce Subsequent Treatment Failure More Effectively Among Depressed Patients with a Higher Degree of Treatment Resistance? A Meta-Analysis of Randomized Controlled Trials. Int J Neuropsychopharmacol 2015, 18(8).

61. Luan S, Wan H, Zhang L, Zhao H: Efficacy, acceptability, and safety of adjunctive aripiprazole in treatment-resistant depression: a meta-analysis of randomized controlled trials. Neuropsychiatr Dis Treat 2018, 14:467-477.

62. Berman RM, Marcus RN, Swanink R, McQuade RD, Carson WH, Corey-Lisle PK, Khan A: The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2007, 68(6):843-853.

63. Berman RM, Fava M, Thase ME, Trivedi MH, Swanink R, McQuade RD, Carson WH, Adson D, Taylor L, Hazel J et al: Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants. CNS Spectr 2009, 14(4):197-206.

64. Marcus RN, McQuade RD, Carson WH, Hennicken D, Fava M, Simon JS, Trivedi MH, Thase ME, Berman RM: The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 2008, 28(2):156-165.

65. Nelson JC, Thase ME, Trivedi MH, Fava M, Han J, Van Tran Q, Pikalov A, Qi Y, Carlson BX, Marcus RN et al: Safety and Tolerability of Adjunctive Aripiprazole in Major Depressive Disorder: A Pooled Post Hoc Analysis (studies CN138-139 and CN138-163). Prim Care Companion J Clin Psychiatry 2009, 11(6):344-352.

66. Fava M, Mischoulon D, Iosifescu D, Witte J, Pencina M, Flynn M, Harper L, Levy M, Rickels K, Pollack M: A double-blind, placebo-controlled study of aripiprazole adjunctive to antidepressant therapy among depressed outpatients with inadequate response to prior antidepressant therapy (ADAPT-A Study). Psychother Psychosom 2012, 81(2):87-97.

67. Kamijima K, Higuchi T, Ishigooka J, Ohmori T, Ozaki N, Kanba S, Kinoshita T, Koyama T: Aripiprazole augmentation to antidepressant therapy in Japanese patients with major depressive disorder: a randomized, double-blind, placebo-controlled study (ADMIRE study). J Affect Disord 2013, 151(3):899-905.

68. Ozaki N, Otsubo T, Kato M, Higuchi T, Ono H, Kamijima K: Efficacy of aripiprazole augmentation in Japanese patients with major depressive disorder: a subgroup analysis and Montgomery-Asberg Depression Rating Scale and Hamilton Rating Scale for Depression item analyses of the Aripiprazole Depression Multicenter Efficacy study. Psychiatry Clin Neurosci 2015, 69(1):34-42.

69. Kamijima K, Yasuda M, Yamamura K, Fukuta Y: Real-world effectiveness and safety of aripiprazole augmentation therapy in patients with major depressive disorder. Curr Med Res Opin 2018, 34(12):2105-2112.

70. Clayton AH, Baker RA, Sheehan JJ, Cain ZJ, Forbes RA, Marler SV, Marcus R, Berman RM, Thase ME: Comparison of adjunctive use of aripiprazole with bupropion or selective serotonin reuptake inhibitors/serotonin-norepinephrine reuptake inhibitors: analysis of patients beginning adjunctive treatment in a 52-week, open-label study. BMC Res Notes 2014, 7:459.

71. Nelson JC, Rahman Z, Laubmeier KK, Eudicone JM, McQuade RD, Berman RM, Marcus RN, Baker RA, Sheehan JJ: Efficacy of adjunctive aripiprazole in patients with major depressive disorder whose symptoms worsened with antidepressant monotherapy. CNS Spectr 2014, 19(6):528-534.

72. Muzina DJ, Chambers JS, Camacho TA, Eudicone JM, Forbes RA, Berman RM, Baker RA: Adjunctive aripiprazole for depression: predictive value of early assessment. Am J Manag Care 2011, 17(12):793-801.

73. Mischoulon D, Witte J, Levy M, Papakostas GI, Pet LR, Hsieh WH, Pencina MJ, Ward S, Pollack MH, Fava M: Efficacy of dose increase among nonresponders to low-dose aripiprazole augmentation in patients with inadequate response to antidepressant treatment: a randomized, double-blind, placebo-controlled, efficacy trial. J Clin Psychiatry 2012, 73(3):353-357.

74. Stahl SM: Mechanism of action of brexpiprazole: comparison with aripiprazole. CNS Spectr 2016, 21(1):1-6.

75. Yoon S, Jeon SW, Ko YH, Patkar AA, Masand PS, Pae CU, Han C: Adjunctive Brexpiprazole as a Novel Effective Strategy for Treating Major Depressive Disorder: A Systematic Review and Meta-Analysis. J Clin Psychopharmacol 2017, 37(1):46-53.

76. Citrome L: Brexpiprazole for schizophrenia and as adjunct for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antipsychotic - what is the number

needed to treat, number needed to harm and likelihood to be helped or harmed? Int J Clin Pract 2015, 69(9):978-997.

77. Thase M, Youakim J, Skuban A, Hobart M, Augustine C, Zhang P, McQuade R, Carson W, Nyilas M, Sanchez R et al: Efficacy and Safety of Adjunctive Brexpiprazole 2 mg in Major Depressive Disorder: A Phase 3, Randomized, Placebo-Controlled Study in Patients With Inadequate Response to Antidepressants. The Journal of clinical psychiatry 2015, 76.

78. Thase M, Youakim J, Skuban A, Hobart M, Zhang P, McQuade R, Nyilas M, Carson W, Sanchez R, Eriksson H: Adjunctive Brexpiprazole 1 and 3 mg for Patients With Major Depressive Disorder Following Inadequate Response to Antidepressants. The Journal of clinical psychiatry 2015, 76.

79. Hobart M, Skuban A, Zhang P, Augustine C, Brewer C, Hefting N, Sanchez R, McQuade RD: A Randomized, Placebo-Controlled Study of the Efficacy and Safety of Fixed-Dose Brexpiprazole 2 mg/d as Adjunctive Treatment of Adults With Major Depressive Disorder. J Clin Psychiatry 2018, 79(4).

80. Hobart M, Zhang P, Skuban A, Brewer C, Hefting N, Sanchez R, McQuade RD: A Long-Term, Open-Label Study to Evaluate the Safety and Tolerability of Brexpiprazole as Adjunctive Therapy in Adults With Major Depressive Disorder. J Clin Psychopharmacol 2019, 39(3):203-209.

81. Bauer M, Hefting N, Lindsten A, Josiassen MK, Hobart M: A randomised, placebo-controlled 24-week study evaluating adjunctive brexpiprazole in patients with major depressive disorder. Acta Neuropsychiatr 2019, 31(1):27-35.

82. Bobo WV, Shelton RC: Olanzapine and fluoxetine combination therapy for treatment-resistant depression: review of efficacy, safety, and study design issues. Neuropsychiatr Dis Treat 2009, 5:369-383.

83. Shelton R, Tollefson G, Tohen M, Stahl S, Gannon K, Jacobs T, Buras W, Bymaster F, Zhang W, Spencer K et al: A Novel Augmentation Strategy for Treating Resistant Major Depression. The American journal of psychiatry 2001, 158:131-134.

84. Shelton RC, Williamson DJ, Corya SA, Sanger TM, Van Campen LE, Case M, Briggs SD, Tollefson GD: Olanzapine/fluoxetine combination for treatment-resistant depression: a controlled study of SSRI and nortriptyline resistance. J Clin Psychiatry 2005, 66(10):1289-1297.

85. Thase ME, Corya SA, Osuntokun O, Case M, Henley DB, Sanger TM, Watson SB, Dube S: A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder. J Clin Psychiatry 2007, 68(2):224-236.

86. Parker G, Brotchie H, Parker K: Is combination olanzapine and antidepressant medication associated with a more rapid response trajectory than antidepressant alone? Am J Psychiatry 2005, 162(4):796-798.

87. Corya SA, Andersen SW, Detke HC, Kelly LS, Van Campen LE, Sanger TM, Williamson DJ, Dube S: Long-term antidepressant efficacy and safety of olanzapine/fluoxetine combination: a 76-week open-label study. J Clin Psychiatry 2003, 64(11):1349-1356.

88. Bobo WV, Shelton RC: Fluoxetine and olanzapine combination therapy in treatment-resistant major depression: review of efficacy and safety data. Expert Opin Pharmacother 2009, 10(13):2145-2159.

89. Boku S, Inoue T, Honma H, Honma H, Nakagawa S, Koyama T: Olanzapine augmentation of milnacipran for stage 2 treatment-resistant major depression: an open study. Hum Psychopharmacol 2011, 26(3):237-241.

90. Bauer M, Pretorius HW, Constant EL, Earley WR, Szamosi J, Brecher M: Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study. J Clin Psychiatry 2009, 70(4):540-549.

91. El-Khalili N, Joyce M, Atkinson S, Buynak RJ, Datto C, Lindgren P, Eriksson H: Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study. Int J Neuropsychopharmacol 2010, 13(7):917-932.

92. Garakani A, Martinez JM, Marcus S, Weaver J, Rickels K, Fava M, Hirschowitz J: A randomized, double-blind, and placebo-controlled trial of quetiapine augmentation of fluoxetine in major depressive disorder. Int Clin Psychopharmacol 2008, 23(5):269-275.

93. Bauer M, Demyttenaere K, El-Khalili N, Thase ME, Papakostas GI, Szamosi J, Earley WR, Eriksson H: Pooled analysis of adjunct extended-release quetiapine fumarate in patients with major depressive disorder according to ongoing SSRI or SNRI treatment. Int Clin Psychopharmacol 2014, 29(1):16-25.

94. Mahmoud RA, Pandina GJ, Turkoz I, Kosik-Gonzalez C, Canuso CM, Kujawa MJ, Gharabawi-Garibaldi GM: Risperidone for treatment-refractory major depressive disorder: a randomized trial. Annals of internal medicine 2007, 147(9):593-602.

95. Keitner GI, Garlow SJ, Ryan CE, Ninan PT, Solomon DA, Nemeroff CB, Keller MB: A randomized, placebo-controlled trial of risperidone augmentation for patients with difficult-to-treat unipolar, non-psychotic major depression. J Psychiatr Res 2009, 43(3):205-214.

96. Rapaport MH, Gharabawi GM, Canuso CM, Mahmoud RA, Keller MB, Bossie CA, Turkoz I, Lasser RA, Loescher A, Bouhours P et al: Effects of risperidone augmentation in patients with treatment-resistant depression: Results of open-label treatment followed by double-blind continuation. Neuropsychopharmacology 2006, 31(11):2505-2513.

97. Owenby RK, Brown LT, Brown JN: Use of risperidone as augmentation treatment for major depressive disorder. Ann Pharmacother 2011, 45(1):95-100.

98. Bauer M, Adli M, Ricken R, Severus E, Pilhatsch M: Role of lithium augmentation in the management of major depressive disorder. CNS Drugs 2014, 28(4):331-342.

99. Crossley NA, Bauer M: Acceleration and augmentation of antidepressants with lithium for depressive disorders: two meta-analyses of randomized, placebo-controlled trials. J Clin Psychiatry 2007, 68(6):935-940.

100. Nelson JC, Baumann P, Delucchi K, Joffe R, Katona C: A systematic review and meta-analysis of lithium augmentation of tricyclic and second generation antidepressants in major depression. J Affect Disord 2014, 168:269-275.

101. Alevizos B, Alevizos E, Leonardou A, Zervas I: Low dosage lithium augmentation in venlafaxine resistant depression: an open-label study. Psychiatriki 2012, 23(2):143-148.

102. Sugawara H, Sakamoto K, Harada T, Ishigooka J: Predictors of efficacy in lithium augmentation for treatment-resistant depression. J Affect Disord 2010, 125(1-3):165-168.

103. Nierenberg AA, Papakostas GI, Petersen T, Montoya HD, Worthington JJ, Tedlow J, Alpert JE, Fava M: Lithium augmentation of nortriptyline for subjects resistant to multiple antidepressants. J Clin Psychopharmacol 2003, 23(1):92-95.

104. Valerio MP, Martino DJ: Differential response to lithium between melancholic and non-melancholic unipolar depression. Psychiatry Res 2018, 269:183-184.

105. Harter M, Klesse C, Bermejo I, Schneider F, Berger M: Unipolar depression: diagnostic and therapeutic recommendations from the current S3/National Clinical Practice Guideline. Dtsch Arztebl Int 2010, 107(40):700-708.

106. Cooper-Kazaz R, Lerer B: Efficacy and safety of triiodothyronine supplementation in patients with major depressive disorder treated with specific serotonin reuptake inhibitors. Int J Neuropsychopharmacol 2008, 11(5):685-699.

107. Abraham G, Milev R, Stuart Lawson J: T3 augmentation of SSRI resistant depression. J Affect Disord 2006, 91(2-3):211-215.

108. Aronson R, Offman HJ, Joffe RT, Naylor CD: Triiodothyronine augmentation in the treatment of refractory depression. A meta-analysis. Arch Gen Psychiatry 1996, 53(9):842-848.

109. Sokolov ST, Levitt AJ, Joffe RT: Thyroid hormone levels before unsuccessful antidepressant therapy are associated with later response to T3 augmentation. Psychiatry Res 1997, 69(2-3):203-206.

110. Garlow SJ, Dunlop BW, Ninan PT, Nemeroff CB: The combination of triiodothyronine (T3) and sertraline is not superior to sertraline monotherapy in the treatment of major depressive disorder. J Psychiatr Res 2012, 46(11):1406-1413.

111. Posternak M, Novak S, Stern R, Hennessey J, Joffe R, Prange A, Jr., Zimmerman M: A pilot effectiveness study: placebo-controlled trial of adjunctive L-triiodothyronine (T3) used to accelerate and potentiate the antidepressant response. Int J Neuropsychopharmacol 2008, 11(1):15-25.

112. Kelly TF, Lieberman DZ: Long term augmentation with T3 in refractory major depression. J Affect Disord 2009, 115(1-2):230-233.

113. Cooke RG, Joffe RT, Levitt AJ: T3 augmentation of antidepressant treatment in T4-replaced thyroid patients. J Clin Psychiatry 1992, 53(1):16-18.

114. Rosenthal LJ, Goldner WS, O'Reardon JP: T3 augmentation in major depressive disorder: safety considerations. Am J Psychiatry 2011, 168(10):1035-1040.

115. Henssler J, Bschor T, Baethge C: Combining Antidepressants in Acute Treatment of Depression: A Meta-Analysis of 38 Studies Including 4511 Patients. Canadian journal of psychiatry Revue canadienne de psychiatrie 2016, 61(1):29-43.

116. Keks NA, Burrows GD, Copolov DL, Newton R, Paoletti N, Schweitzer I, Tiller J: Beyond the evidence: is there a place for antidepressant combinations in the pharmacotherapy of depression? Med J Aust 2007, 186(3):142-144.

117. Blier P, Ward HE, Tremblay P, Laberge L, Hebert C, Bergeron R: Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study. Am J Psychiatry 2010, 167(3):281-288.

118. Jha MK, Malchow AL, Grannemann BD, Rush AJ, Trivedi MH: Do baseline sub-threshold hypomanic symptoms affect acute-phase antidepressant outcome in outpatients with major depressive disorder? Preliminary findings from the randomized CO-MED trial. Neuropsychopharmacology 2018, 43(11):2197-2203.

119. Rush AJ, Trivedi MH, Stewart JW, Nierenberg AA, Fava M, Kurian BT, Warden D, Morris DW, Luther JF, Husain MM et al: Combining medications to enhance depression outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study. Am J Psychiatry 2011, 168(7):689-701.

120. Rocha FL, Fuzikawa C, Riera R, Hara C: Combination of antidepressants in the treatment of major depressive disorder: a systematic review and meta-analysis. J Clin Psychopharmacol 2012, 32(2):278-281.

121. Patel K, Allen S, Haque MN, Angelescu I, Baumeister D, Tracy DK: Bupropion: a systematic review and meta-analysis of effectiveness as an antidepressant. Ther Adv Psychopharmacol 2016, 6(2):99-144.

122. Gulrez G, Badyal DK, Deswal RS, Sharma A: Bupropion as an augmenting agent in patients of depression with partial response. Basic Clin Pharmacol Toxicol 2012, 110(3):227-230.

123. Fornaro M, Martino M, Mattei C, Prestia D, Vinciguerra V, De Berardis D, De Pasquale C, Iasevoli F, Mungo S, Fornaro P: Duloxetine-bupropion combination for treatment-resistant atypical depression: a double-blind, randomized, placebo-controlled trial. Eur Neuropsychopharmacol 2014, 24(8):1269-1278.

124. Leuchter AF, Lesser IM, Trivedi MH, Rush AJ, Morris DW, Warden D, Fava M, Wisniewski SR, Luther JF, Perales M et al: An open pilot study of the combination of escitalopram and bupropion-SR for outpatients with major depressive disorder. J Psychiatr Pract 2008, 14(5):271-280.

125. DeBattista C, Solvason HB, Poirier J, Kendrick E, Schatzberg AF: A prospective trial of bupropion SR augmentation of partial and non-responders to serotonergic antidepressants. J Clin Psychopharmacol 2003, 23(1):27-30.

126. Spier SA: Use of bupropion with SRIs and venlafaxine. Depress Anxiety 1998, 7(2):73-75.

127. Papakostas GI, Worthington JJ, 3rd, Iosifescu DV, Kinrys G, Burns AM, Fisher LB, Homberger CH, Mischoulon D, Fava M: The combination of duloxetine and bupropion for treatment-resistant major depressive disorder. Depress Anxiety 2006, 23(3):178-181.

128. Nasr S, Wendt B, Popli A, Crayton J: Comparing outcomes of adjunctive treatment in depression: aripiprazole versus bupropion. J Affect Disord 2014, 162:50-54.

129. Bodkin JA, Lasser RA, Wines JD, Jr., Gardner DM, Baldessarini RJ: Combining serotonin reuptake inhibitors and bupropion in partial responders to antidepressant monotherapy. J Clin Psychiatry 1997, 58(4):137-145.

130. Lam RW, Hossie H, Solomons K, Yatham LN: Citalopram and bupropion-SR: combining versus switching in patients with treatment-resistant depression. J Clin Psychiatry 2004, 65(3):337-340.

131. Stewart JW, McGrath PJ, Blondeau C, Deliyannides DA, Hellerstein D, Norris S, Amat J, Pilowsky DJ, Tessier P, Laberge L et al: Combination antidepressant therapy for major depressive disorder: Speed and probability of remission. Journal of psychiatric research 2014, 52:7-14.

132. Taylor MJ, Rudkin L, Bullemor-Day P, Lubin J, Chukwujekwu C, Hawton K: Strategies for managing sexual dysfunction induced by antidepressant medication. Cochrane Database Syst Rev 2013(5):Cd003382.

133. SwitchRx [https://www.switchrx.com/antidepressants.php/switch]

134. Blier P, Gobbi G, Turcotte J, Montigny C, Boucher N, Hébert C, Debonnel G: Mirtazapine and paroxetine in major depression: A comparison of monotherapy versus their combination from treatment initiation. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 2009, 19:457-465.

135. Kessler D, Burns A, Tallon D, Lewis G, MacNeill S, Round J, Hollingworth W, Chew-Graham C, Anderson I, Campbell J et al: Combining mirtazapine with SSRIs or SNRIs for treatment-resistant depression: the MIR RCT. Health Technol Assess 2018, 22(63):1-136.

136. Carpenter LL, Yasmin S, Price LH: A double-blind, placebo-controlled study of antidepressant augmentation with mirtazapine. Biol Psychiatry 2002, 51(2):183-188.

137. Goss AJ, Kaser M, Costafreda SG, Sahakian BJ, Fu CH: Modafinil augmentation therapy in unipolar and bipolar depression: a systematic review and meta-analysis of randomized controlled trials. J Clin Psychiatry 2013, 74(11):1101-1107.

138. Candy B, Jones L, Williams R, Tookman A, King M: Psychostimulants for depression. Cochrane Database of Systematic Reviews 2008(2).

139. Fava M, Thase ME, DeBattista C: A multicenter, placebo-controlled study of modafinil augmentation in partial responders to selective serotonin reuptake inhibitors with persistent fatigue and sleepiness. J Clin Psychiatry 2005, 66(1):85-93.

140. The Management of Major Depressive Disorder Work Group: VA/DoD Clinical Practice Guideline for the Management of Major Depressive Disorder. Online: Department of Veterans Affairs, Department of Defense; 2022.

141. Papakostas GI, Salloum NC, Hock RS, Jha MK, Murrough JW, Mathew SJ, Iosifescu DV, Fava M: Efficacy of Esketamine Augmentation in Major Depressive Disorder: A Meta-Analysis. J Clin Psychiatry 2020, 81(4).

142. Citrome L, DiBernardo A, Singh J: Appraising esketamine nasal spray for the management of treatment-resistant depression in adults: Number needed to treat, number needed to harm, and likelihood to be helped or harmed. J Affect Disord 2020, 271:228-238.

143. Zheng W, Cai DB, Xiang YQ, Zheng W, Jiang WL, Sim K, Ungvari GS, Huang X, Huang XX, Ning YP et al: Adjunctive intranasal esketamine for major depressive disorder: A systematic review of randomized double-blind controlled-placebo studies. J Affect Disord 2020, 265:63-70.

144. McIntyre RS, Carvalho IP, Lui LMW, Majeed A, Masand PS, Gill H, Rodrigues NB, Lipsitz O, Coles AC, Lee Y et al: The effect of intravenous, intranasal, and oral ketamine in mood disorders: A meta-analysis. J Affect Disord 2020, 276:576-584.

145. Esketamine for treatment-resistant depression. Drug and Therapeutics Bulletin 2020, 58(12):183-188.

146. Wajs E, Aluisio L, Holder R, Daly EJ, Lane R, Lim P, George JE, Morrison RL, Sanacora G, Young AH et al: Esketamine Nasal Spray Plus Oral Antidepressant in Patients With Treatment-Resistant Depression: Assessment of Long-Term Safety in a Phase 3, Open-Label Study (SUSTAIN-2). J Clin Psychiatry 2020, 81(3).

147. Ochs-Ross R, Daly EJ, Zhang Y, Lane R, Lim P, Morrison RL, Hough D, Manji H, Drevets WC, Sanacora G et al: Efficacy and Safety of Esketamine Nasal Spray Plus an Oral Antidepressant in Elderly Patients With Treatment-Resistant Depression-TRANSFORM-3. Am J Geriatr Psychiatry 2020, 28(2):121-141.

148. Solmi M, Veronese N, Zaninotto L, Loos M, Gao K, Schaffer A, Reis C, Normann C, Anghelescu I, Correll C: Lamotrigine compared to placebo and other agents with antidepressant activity in patients with unipolar and bipolar depression: A comprehensive meta-analysis of efficacy and safety outcomes in short-term trials. CNS spectrums 2016, 21:403-418.

149. Joffe RT, Singer W: A comparison of triiodothyronine and thyroxine in the potentiation of tricyclic antidepressants. Psychiatry Res 1990, 32(3):241-251.

150. Papakostas GI, Fava M, Baer L, Swee MB, Jaeger A, Bobo WV, Shelton RC: Ziprasidone Augmentation of Escitalopram for Major Depressive Disorder: Efficacy Results From a Randomized, Double-Blind, Placebo-Controlled Study. Am J Psychiatry 2015, 172(12):1251-1258.

151. Fava M, Rosenbaum JF, McGrath PJ, Stewart JW, Amsterdam JD, Quitkin FM: Lithium and tricyclic augmentation of fluoxetine treatment for resistant major depression: a double-blind, controlled study. Am J Psychiatry 1994, 151(9):1372-1374.

152. Fava M, Alpert J, Nierenberg A, Lagomasino I, Sonawalla S, Tedlow J, Worthington J, Baer L, Rosenbaum JF: Double-blind study of high-dose fluoxetine versus lithium or desipramine augmentation of fluoxetine in partial responders and nonresponders to fluoxetine. J Clin Psychopharmacol 2002, 22(4):379-387.

153. Coppen A, Bailey J: Enhancement of the antidepressant action of fluoxetine by folic acid: a randomised, placebo controlled trial. J Affect Disord 2000, 60(2):121-130.

154. Kelly CB, McDonnell AP, Johnston TG, Mulholland C, Cooper SJ, McMaster D, Evans A, Whitehead AS: The MTHFR C677T polymorphism is associated with depressive episodes in patients from Northern Ireland. J Psychopharmacol 2004, 18(4):567-571.

155. Papakostas GI, Shelton RC, Zajecka JM, Etemad B, Rickels K, Clain A, Baer L, Dalton ED, Sacco GR, Schoenfeld D et al: L-methylfolate as adjunctive therapy for SSRI-resistant major depression: results of two randomized, double-blind, parallel-sequential trials. Am J Psychiatry 2012, 169(12):1267-1274.

156. Shelton RC, Sloan Manning J, Barrentine LW, Tipa EV: Assessing Effects of l-Methylfolate in Depression Management: Results of a Real-World Patient Experience Trial. Prim Care Companion CNS Disord 2013, 15(4).

157. Passeri M, Cucinotta D, Abate G, Senin U, Ventura A, Stramba Badiale M, Diana R, La Greca P, Le Grazie C: Oral 5'-methyltetrahydrofolic acid in senile organic mental disorders with depression: results of a double-blind multicenter study. Aging (Milano) 1993, 5(1):63-71.

158. Godfrey PS, Toone BK, Carney MW, Flynn TG, Bottiglieri T, Laundy M, Chanarin I, Reynolds EH: Enhancement of recovery from psychiatric illness by methylfolate. Lancet 1990, 336(8712):392-395.

159. Guaraldi GP, Fava M, Mazzi F, la Greca P: An open trial of methyltetrahydrofolate in elderly depressed patients. Ann Clin Psychiatry 1993, 5(2):101-105.

160. Paton C, Ferrier IN: SSRIs and gastrointestinal bleeding. BMJ 2005, 331(7516):529-530.

161. Meijer WE, Heerdink ER, Nolen WA, Herings RM, Leufkens HG, Egberts AC: Association of risk of abnormal bleeding with degree of serotonin reuptake inhibition by antidepressants. Arch Intern Med 2004, 164(21):2367-2370.

162. Cheng YL, Hu HY, Lin XH, Luo JC, Peng YL, Hou MC, Lin HC, Lee FY: Use of SSRI, But Not SNRI, Increased Upper and Lower Gastrointestinal Bleeding: A Nationwide Population-Based Cohort Study in Taiwan. Medicine (Baltimore) 2015, 94(46):e2022.

163. Wang SM, Han C, Bahk WM, Lee SJ, Patkar AA, Masand PS, Pae CU: Addressing the Side Effects of Contemporary Antidepressant Drugs: A Comprehensive Review. Chonnam Med J 2018, 54(2):101-112.

164. Sanis Health Inc: Trazodone. In: Health Canada Monograph. 2017.

165. Allergan: Vilazodone. In: CA Product Monograph. 2019.

166. Lundbeck: Vortioxetine. In: CA Product Monograph. 2019.

167. Dalton SO, Johansen C, Mellemkjaer L, Norgard B, Sorensen HT, Olsen JH: Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study. Arch Intern Med 2003, 163(1):59-64.

168. Carvalho AF, Sharma MS, Brunoni AR, Vieta E, Fava GA: The Safety, Tolerability and Risks Associated with the Use of Newer Generation Antidepressant Drugs: A Critical Review of the Literature. Psychother Psychosom 2016, 85(5):270-288.

169. Na KS, Jung HY, Cho SJ, Cho SE: Can we recommend mirtazapine and bupropion for patients at risk for bleeding?: A systematic review and meta-analysis. J Affect Disord 2018, 225:221-226.

170. Park LT, Zarate CA, Jr.: Depression in the Primary Care Setting. The New England Journal of Medicine 2019, 380(23):2279-2280.

171. Henssler J, Kurschus M, Franklin J, Bschor T, Baethge C: Trajectories of Acute Antidepressant Efficacy: How Long to Wait for Response? A Systematic Review and Meta-Analysis of Long-Term, Placebo-Controlled Acute Treatment Trials. J Clin Psychiatry 2018, 79(3).

172. Lewis G, Duffy L, Ades A, Amos R, Araya R, Brabyn S, Button KS, Churchill R, Derrick C, Dowrick C et al: The clinical effectiveness of sertraline in primary care and the role of depression severity and duration

(PANDA): a pragmatic, double-blind, placebo-controlled randomised trial. The Lancet Psychiatry 2019, 6(11):903-914.

173. McCarron RM, Shapiro B, Rawles J, Luo J: Depression. Annals of internal medicine 2021, 174(5):Itc65-itc80.

174. Park LT, Zarate CA, Jr.: Depression in the Primary Care Setting. N Engl J Med 2019, 380(6):559-568.

175. Arnold MJ, Fulleborn S, Farrell J: Medications for Treatment-Resistant Depression in Adults. Am Fam Physician 2021, 103(1):16-18.

176. Jensen B RL: Antidepressants: Comparison Chart. May 2019 edn. RxFiles.ca: RxFiles Academic Detailing; 2019.

177. Psychiatrynet [http://wiki.psychiatrienet.nl/index.php/SwitchAntidepressants]

178. Jensen B RL: Antipsychotics: Comparison Chart. Nov 2019 edn. RxFiles.ca: RxFiles Academic Detailing; 2019.

179. Jibson M: Second-generation antipsychotic medications: Pharmacology, administration, and side effects. In: UpToDate. Edited by Marder S; 2019.

180. Muench J, Hamer AM: Adverse effects of antipsychotic medications. Am Fam Physician 2010, 81(5):617-622.

181. Arnow B, Blasey C, Williams L, Palmer D, Rekshan W, Schatzberg A, Etkin A, Kulkarni J, Luther J, Rush A: Depression Subtypes in Predicting Antidepressant Response: A Report From the iSPOT-D Trial. American Journal of Psychiatry 2015, 172.

182. Jha MK, Minhajuddin A, Gadad BS, Greer T, Grannemann B, Soyombo A, Mayes TL, Rush AJ, Trivedi MH: Can C-reactive protein inform antidepressant medication selection in depressed outpatients? Findings from the CO-MED trial. Psychoneuroendocrinology 2017, 78:105-113.

183. Arteaga-Henríquez G, Simon MS, Burger B, Weidinger E, Wijkhuijs A, Arolt V, Birkenhager TK, Musil R, Müller N, Drexhage HA: Low-Grade Inflammation as a Predictor of Antidepressant and Anti-Inflammatory Therapy Response in MDD Patients: A Systematic Review of the Literature in Combination With an Analysis of Experimental Data Collected in the EU-MOODINFLAME Consortium. Front Psychiatry 2019, 10:458-458.

184. Keks N, Hope J, Keogh S: Switching and stopping antidepressants. Aust Prescr 2016, 39(3):76-83.

185. Henssler J, Heinz A, Brandt L, Bschor T: Antidepressant Withdrawal and Rebound Phenomena. Dtsch Arztebl Int 2019, 116(20):355-361.

186. Zafra-Tanaka JH, Goicochea-Lugo S, Villarreal-Zegarra D, Taype-Rondan A: Characteristics and quality of clinical practice guidelines for depression in adults: a scoping review. BMC Psychiatry 2019, 19(1):76.

187. Bahr R, Lopez A, Rey JA: Intranasal Esketamine (Spravato(TM)) for Use in Treatment-Resistant Depression In Conjunction With an Oral Antidepressant. P t 2019, 44(6):340-375.

188. Andrade C: Relative Efficacy and Acceptability of Antidepressant Drugs in Adults With Major Depressive Disorder: Commentary on a Network Meta-Analysis. J Clin Psychiatry 2018, 79(2).

189. Gabriel FC, de Melo DO, Fráguas R, Leite-Santos NC, Mantovani da Silva RA, Ribeiro E: Pharmacological treatment of depression: A systematic review comparing clinical practice guideline recommendations. PLoS One 2020, 15(4):e0231700.

190. Powell JG, Garland S, Preston K, Piszczatoski C: Brexanolone (Zulresso): Finally, an FDA-Approved Treatment for Postpartum Depression. Ann Pharmacother 2020, 54(2):157-163.

191. Athreya A, Brückl T, Binder E, Rush A, Biernacka J, Frye M, Neavin D, Skime M, Monrad D, Iyer R et al: Prediction of short-term antidepressant response using probabilistic graphical models with replication across multiple drugs and treatment settings. Neuropsychopharmacology 2021:1-11.

192. Tomlinson A, Furukawa TA, Efthimiou O, Salanti G, De Crescenzo F, Singh I, Cipriani A: Personalise antidepressant treatment for unipolar depression combining individual choices, risks and big data (PETRUSHKA): rationale and protocol. Evid Based Ment Health 2020, 23(2):52-56.

193. Kraus C, Kadriu B, Lanzenberger R, Zarate CA, Jr., Kasper S: Prognosis and improved outcomes in major depression: a review. Transl Psychiatry 2019, 9(1):127.

194. Schatzberg AF, Blier P, Delgado PL, Fava M, Haddad PM, Shelton RC: Antidepressant discontinuation syndrome: consensus panel recommendations for clinical management and additional research. J Clin Psychiatry 2006, 67 Suppl 4:27-30.

195. National Institute for Health and Care Excellence: Depression in Adults with a Chronic Physical Health Problem: Treatment and Management. 2010.

196. Baldwin DS, Montgomery SA, Nil R, Lader M: Discontinuation symptoms in depression and anxiety disorders. Int J Neuropsychopharmacol 2007, 10(1):73-84.

197. Fava M: Prospective studies of adverse events related to antidepressant discontinuation. J Clin Psychiatry 2006, 67 Suppl 4:14-21.

198. Taylor D, Stewart S, Connolly A: Antidepressant withdrawal symptoms-telephone calls to a national medication helpline. J Affect Disord 2006, 95(1-3):129-133.

199. American Psychiatric Association: Practice Guideline for the Treatment of Patients with Major Depressive Disorder. Third Edition edn: American Psychiatric Association; 2010.

200. Perahia DG, Pritchett YL, Kajdasz DK, Bauer M, Jain R, Russell JM, Walker DJ, Spencer KA, Froud DM, Raskin J et al: A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder. J Psychiatr Res 2008, 42(1):22-34.

201. Gartlehner G, Hansen RA, Morgan LC, Thaler K, Lux L, Van Noord M, Mager U, Thieda P, Gaynes BN, Wilkins T et al: Comparative benefits and harms of second-generation antidepressants for treating major depressive disorder: an updated meta-analysis. Annals of internal medicine 2011, 155(11):772-785.

202. National Institute for Health and Care Excellence: Depression: Evidence Update. 2012.

203. Schueler YB, Koesters M, Wieseler B, Grouven U, Kromp M, Kerekes MF, Kreis J, Kaiser T, Becker T, Weinmann S: A systematic review of duloxetine and venlafaxine in major depression, including unpublished data. Acta psychiatrica Scandinavica 2011, 123(4):247-265.

204. Hicks JK, Bishop JR, Sangkuhl K, Muller DJ, Ji Y, Leckband SG, Leeder JS, Graham RL, Chiulli DL, A LL et al: Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors. Clinical pharmacology and therapeutics 2015, 98(2):127-134.

205. Nierenberg AA, Farabaugh AH, Alpert JE, Gordon J, Worthington JJ, Rosenbaum JF, Fava M: Timing of onset of antidepressant response with fluoxetine treatment. Am J Psychiatry 2000, 157(9):1423-1428.

206. Nierenberg AA, McLean NE, Alpert JE, Worthington JJ, Rosenbaum JF, Fava M: Early nonresponse to fluoxetine as a predictor of poor 8-week outcome. Am J Psychiatry 1995, 152(10):1500-1503.

207. Szegedi A, Jansen WT, van Willigenburg AP, van der Meulen E, Stassen HH, Thase ME: Early improvement in the first 2 weeks as a predictor of treatment outcome in patients with major depressive disorder: a meta-analysis including 6562 patients. J Clin Psychiatry 2009, 70(3):344-353.

208. Szegedi A, Muller MJ, Anghelescu I, Klawe C, Kohnen R, Benkert O: Early improvement under mirtazapine and paroxetine predicts later stable response and remission with high sensitivity in patients with major depression. J Clin Psychiatry 2003, 64(4):413-420.

209. Dreimuller N, Wagner S, Engel A, Braus DF, Roll SC, Elsner S, Tadic A, Lieb K: Predictors of the effectiveness of an early medication change strategy in patients with major depressive disorder. BMC Psychiatry 2019, 19(1):24.

210. Bobo WV, Chen H, Trivedi MH, Stewart JW, Nierenberg AA, Fava M, Kurian BT, Warden D, Morris DW, Luther JF et al: Randomized comparison of selective serotonin reuptake inhibitor (escitalopram) monotherapy and antidepressant combination pharmacotherapy for major depressive disorder with melancholic features: a CO-MED report. J Affect Disord 2011, 133(3):467-476.

211. Kunugi H, Hori H, Ogawa S: Biochemical markers subtyping major depressive disorder. Psychiatry Clin Neurosci 2015, 69(10):597-608.

212. Keller MB: Issues in treatment-resistant depression. J Clin Psychiatry 2005, 66 Suppl 8:5-12.

213. Berlim MT, Turecki G: What is the meaning of treatment resistant/refractory major depression (TRD)? A systematic review of current randomized trials. Eur Neuropsychopharmacol 2007, 17(11):696-707.

214. MacQueen G, Santaguida P, Keshavarz H, Jaworska N, Levine M, Beyene J, Raina P: Systematic Review of Clinical Practice Guidelines for Failed Antidepressant Treatment Response in Major Depressive Disorder, Dysthymia, and Subthreshold Depression in Adults. Canadian journal of psychiatry Revue canadienne de psychiatrie 2017, 62(1):11-23.

215. Rush AJ, Fava M, Wisniewski SR, Lavori PW, Trivedi MH, Sackeim HA, Thase ME, Nierenberg AA, Quitkin FM, Kashner TM et al: Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. Control Clin Trials 2004, 25(1):119-142.

216. Gaynes BN, Dusetzina SB, Ellis AR, Hansen RA, Farley JF, Miller WC, Sturmer T: Treating depression after initial treatment failure: directly comparing switch and augmenting strategies in STAR*D. J Clin Psychopharmacol 2012, 32(1):114-119.

217. Bauer M, Dopfmer S: Lithium augmentation in treatment-resistant depression: meta-analysis of placebo-controlled studies. J Clin Psychopharmacol 1999, 19(5):427-434.

218. Adli M, Wiethoff K, Baghai TC, Fisher R, Seemuller F, Laakmann G, Brieger P, Cordes J, Malevani J, Laux G et al: How Effective Is Algorithm-Guided Treatment for Depressed Inpatients? Results from the Randomized Controlled Multicenter German Algorithm Project 3 Trial. Int J Neuropsychopharmacol 2017, 20(9):721-730.

219. Bschor T, Baethge C: No evidence for switching the antidepressant: systematic review and meta-analysis of RCTs of a common therapeutic strategy. Acta psychiatrica Scandinavica 2010, 121(3):174-179.

220. Thase ME: No evidence for switching antidepressants in treatment-resistant depressed patients. Evid Based Med 2010, 15(4):120-121.

221. Kato T, Furukawa TA, Mantani A, Kurata K, Kubouchi H, Hirota S, Sato H, Sugishita K, Chino B, Itoh K et al: Optimising first- and second-line treatment strategies for untreated major depressive disorder - the SUND study: a pragmatic, multi-centre, assessor-blinded randomised controlled trial. BMC Med 2018, 16(1):103.

222. Bose A, Tsai J, Li D: Early non-response in patients with severe depression: escitalopram up-titration versus switch to duloxetine. Clin Drug Investig 2012, 32(6):373-385.

223. Irene R, Luis MA, Helena DC, David P, Ramon DJ, Inmaculada G: Switching to duloxetine from selective serotonin reuptake inhibitors in non- or partial responders: Results from a Spanish sample. Int J Psychiatry Clin Pract 2009, 13(2):100-108.

224. Simon G: Unipolar major depression in adults: Choosing initial treatment. In: UpToDate. Edited by P R-B; 2019.

225. NHS WGotCPGotMoDiAfS: Clinical Practice Guideline on the Managment of Depression in Adults. In: Spanish NHS Guideline. guiasalud.es: Ministry of Health, Social Services and Equality; 2015.

226. Ramanuj P, Ferenchick EK, Pincus HA: Depression in primary care: part 2-management. Bmj 2019, 365:l835.

227. Chokka PR, Hankey JR: Assessment and management of sexual dysfunction in the context of depression. Ther Adv Psychopharmacol 2018, 8(1):13-23.

228. Solmi M, Murru A, Pacchiarotti I, Undurraga J, Veronese N, Fornaro M, Stubbs B, Monaco F, Vieta E, Seeman MV et al: Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review. Ther Clin Risk Manag 2017, 13:757-777.

229. Warner CH, Bobo W, Warner C, Reid S, Rachal J: Antidepressant discontinuation syndrome. Am Fam Physician 2006, 74(3):449-456.

230. Bhat V, Kennedy SH: Recognition and management of antidepressant discontinuation syndrome. J Psychiatry Neurosci 2017, 42(4):E7-e8.

231. Berigan TR, Harazin JS: Bupropion-Associated Withdrawal Symptoms: A Case Report. Prim Care Companion J Clin Psychiatry 1999, 1(2):50-51.

232. Baldwin DS, Chrones L, Florea I, Nielsen R, Nomikos GG, Palo W, Reines E: The safety and tolerability of vortioxetine: Analysis of data from randomized placebo-controlled trials and open-label extension studies. Journal of psychopharmacology (Oxford, England) 2016, 30(3):242-252.

233. Beach SR, Celano CM, Sugrue AM, Adams C, Ackerman MJ, Noseworthy PA, Huffman JC: QT Prolongation, Torsades de Pointes, and Psychotropic Medications: A 5-Year Update. Psychosomatics 2018, 59(2):105-122.

234. Crepeau-Gendron G, Brown HK, Shorey C, Madan R, Szabuniewicz C, Koh S, Veinish S, Mah L: Association between citalopram, escitalopram and QTc prolongation in a real-world geriatric setting. J Affect Disord 2019, 250:341-345.

235. Petry N, Lupu R, Gohar A, Larson EA, Peterson C, Williams V, Zhao J, Wilke RA, Hines LJ: CYP2C19 genotype, physician prescribing pattern, and risk for long QT on serotonin selective reuptake inhibitors. Pharmacogenomics 2019, 20(5):343-351.

236. Perahia DG, Quail D, Desaiah D, Corruble E, Fava M: Switching to duloxetine from selective serotonin reuptake inhibitor antidepressants: a multicenter trial comparing 2 switching techniques. J Clin Psychiatry 2008, 69(1):95-105.

237. Romera I, Perez V, Menchon JM, Schacht A, Papen R, Neuhauser D, Abbar M, Picard H, Gilaberte I: Early vs. conventional switching of antidepressants in patients with MDD and moderate to severe pain: a double-blind randomized study. J Affect Disord 2012, 143(1-3):47-55.

238. Nakajima S, Uchida H, Suzuki T, Watanabe K, Hirano J, Yagihashi T, Takeuchi H, Abe T, Kashima H, Mimura M: Is switching antidepressants following early nonresponse more beneficial in acute-phase treatment of depression?: a randomized open-label trial. Prog Neuropsychopharmacol Biol Psychiatry 2011, 35(8):1983-1989.

239. Angita Pharma Inc: AG-Amitriptyline. In: CA Product Monograph. Boucherville, QC; 2021.

240. Upsher-Smith Laboratories: Amitriptyline hydrochloride. In: US Product Monograph. Maple Grove, MN; 2021.

241. Apotex Inc: Apo-amitriptyline. In: CA Product Monograph. Toronto, ON; 2019.

242. Mylan Pharmaceuticals: Amitriptyline. In: US Product Monograph. Morgantown, WV; 2016.

243. Odan Laboratories Ltd.: Odan-Bupropion SR. In: CA Product Monograph. Pointe Claire, QC; 2021.

244. Sun Pharma Canada Inc.: Taro-Bupropion XL. In: CA Product Monograph. Brampton, ON; 2021.

245. Solco Healthcare US LLC: Bupropion hydrochloride tablet extended release (SR). In: US Product Monograph. Somerset, NJ; 2022.

246. Graviti Pharmaceuticals Private Limited: Bupropion hydrochloride extended-release tablet (XL). In: US Product Monograph. Wilmington, DE; 2022.

247. Angita Pharma Inc.: Citalopram. In: CA Product Monograph. Boucherville, QC; 2021.

248. Aurobindo Pharma Limited: Citalopram hydrobromide tablet. In: US Product Monograph. East Windsor, NJ; 2022.

249. JAMP Pharma Corporation: Desvenlafaxine Extended Release Tablets. In: CA Product Monograph. Boucherville, QC; 2022.

250. Greenstone LLC: Desvenlafaxine succinate tablet, extended release. In: US Product Monograph. Peapack, NJ; 2022.

251. Sivem Pharmaceuticals ULC: Duloxetine Delayed-Release Capsules. In: CA Product Monograph. Saint-Laurent, QC; 2022.

252. Lupin Pharmaceuticals Inc.: Duloxetine capsule delayed release. In: US Product Monograph. Baltimore, MD; 2022.

253. Lundbeck Canada Inc.: Cipralex (escitalopram). In: CA Product Monograph. St-Laurent, QC; 2022.

254. Lupin Pharmaceuticals Inc.: Escitalopram tablet. In: US Product Monograph. Baltimore, MD; 2022.

255. Accord Healthcare Inc.: ACH-Fluoxetine. In: CA Product Monograph. Kirkland, QC; 2022.

256. Modavar Pharmaceuticals LLC: Fluoxetine. In: US Product Monograph. Washington, DC; 2022.

257. Pro Doc Ltée: Fluvoxamine. In: CA Product Monograph. Laval, QC; 2022.

258. Allergan Inc.: Fetzima (Levomilnacipran Extended Release Capsule). In: CA Product Monograph. Markham, ON; 2021.

259. Allergan Inc.: Fetzima (levomilnacipran hydrochloride capsule extended release). In: US Product Monograph. Madison, NJ; 2021.

260. Apotex Inc.: Apo-mirtazapine. In: CA Product Monograph. Toronto, ON; 2022.

261. Apotex Corp.: Mirtazapine. In: US Product Monograph. Weston, FL; 2022.

262. Bausch health CI: Manerix (moclobemide). In: CA Product Monograph. Laval, QC; 2021.

263. GlaxoSmithKline Inc.: Paxil (paroxetine). In: CA Product Monograph. Mississauga, ON; 2021.

264. GlaxoSmithKline Inc.: Paxil CR (paroxetine controlled release). In: CA Product Monograph. Mississauga, ON; 2021.

265. Apotex Corp.: Paroxetine. In: US Product Monograph. Weston, FL; 2021.

266. Sebela Pharmaceuticals Inc.: Pexeva (paroxetine mesylate). In: US Product Monograph. Roswell, GA; 2022.

267. Apotex Corp: Paroxetine extended release. In: US Product Monograph. Weston, FL; 2021.

268. Erfa Canada Inc: Nardil (phenelzine). In: CA Product Monograph. Montréal, QC; 2015.

269. Parke-Davis Div of Pfizer Inc: Nardil (phenelzine). In: US Product Monograph. New York, NY; 2020.

270. Mylan Specialty L.P.: Emsam (selegiline patch). In: US Product Monograph. Morgantown, WV; 2020.

271. Pharmascience Inc.: pms-Sertraline. In: CA Product Monograph. Montreal, QC; 2022.

272. Greenstone LLC: Sertraline hydrochloride tablet. In: US Product Monograph. Peapack, NJ; 2022.

273. GlaxoSmithKline: Tranylcypromine. In: CA Product Monograph. 2019.

274. Par Pharmaceutical Inc.: Tranylcypromine. In: US Product Monograph. Chestnut Ridge, NY; 2022.

275. Pro Doc Ltée: Trazodone. In: CA Product Monograph. Laval, QC; 2021.

276. Torrent Pharmaceuticals Limited: Trazodone. In: US Product Monograph. Levittown, PA; 2022.

277. Upjohn Canada ULC: Effexor XR (Venlafaxine Hydrochloride Extended Release Capsules). In: CA Product Monograph. Kirkland, QC; 2022.

278. Acetris Health LLC: Venlafaxine hydrochloride capsule extended release. In: US Product Monograph. Saddle Brook, NJ; 2022.

279. Allergan Inc.: Viibryd (vilazodone hydrochloride). In: CA Product Monograph. Markham, ON; 2021.

280. Allergan Inc.: Viibryd (vilazodone hydrochloride). In: US Product Monograph. Irvine, CA; 2021.

281. Lundbeck Canada Inc.: Trintellix (vortioxetine). In: CA Product Monograph. St-Laurent, QC; 2021.

282. Takeda Pharmaceuticals America Inc.: Trintellix (vortioxetine). In: US Product Monograph. Lexington, MA; 2021.

283. Otsuka Canada Pharmaceutical: Abilify (aripiprazole). In: CA Product Monograph. Saint-Laurent, QC; 2021.

284. Otsuka America Pharmaceutical: Abilify (aripiprazole). In: US Product Monograph. Rockville, MD; 2021.

285. Otsuka Canada Pharmaceutical Inc: Rexulti (brexpiprazole). In: CA Product Monograph. Saint-Laurent, QC; 2020.

286. Otsuka America Pharmaceutical Inc: Rexulti (brexpiprazole). In: US Product Monograph. Rockville, MD; 2021.

287. Janssen Inc: Spravato (esketamine nasal spray). In: CA Product Monograph. Toronto, ON; 2021.

288. Janssen Pharmaceuticals Inc.: Spravato (esketamine hydrochloride solution). In: US Product Monograph. Titusville, NJ; 2020.

289. Bausch Health Canada Inc: Carbolith (lithium). In: CA Product Monograph. Laval, Quebec; 2019.

290. AA Pharma Inc: Lithmax (lithium). In: CA Product Monograph. Vaughan, Ontario; 2013.

291. ANI Pharmaceuticals Inc: Lithium Carbonate extended-release tablet. In: US Product Monograph. Baudette, MN; 2022.

292. Pharmaceuticals C: Lithium Carbonate. In: US Product Monograph. Piscataway, NJ; 2021.

293. Teva Canada Limited: Alertec (modafinil). In: CA Product Monograph. Toronto, ON; 2021.

294. Sanis Health Inc: Olanzapine. In: CA Product Monograph. Brampton, ON; 2021.

295. Eli Lilly and Company: Zyprexa (olanzapine). In: US Product Monograph. Indianapolis, IN; 2022.

296. AstraZeneca Canada Inc: Seroquel (quetiapine). In: CA Product Monograph. Mississauga, ON; 2021.

297. Accord Healthcare: ACH-Quetiapine Fumarate XR. In: CA Product Monograph. Kirkland, QC; 2022.

298. AstraZeneca Pharmaceuticals LP: Seroquel (quetiapine). In: US Product Monograph. Wilmington, DE; 2022.

299. AstraZeneca Pharmaceuticals LP: Seroquel XR - quetiapine extended release. In: US Product Monograph. Wilmington, DE; 2022.

300. Marcan Pharmaceuticals Inc: Mar-risperidone. In: CA Product Monograph. Ottawa, ON; 2022.

301. PD-Rx Pharmaceuticals Inc: Risperdal (risperidone tablet). In: US Product Monograph. Oklahoma City, OK; 2022.

302. Teva Canada Limited: Teva-liothyronine. In: CA Product Monograph. Toronto, ON; 2019.

303. Sun Pharmaceutical Industries Inc: Liothyronine. In: US Product Monograph. Cranbury, NJ; 2021.

304. Hicks JK, Sangkuhl K, Swen JJ, Ellingrod VL, Muller DJ, Shimoda K, Bishop JR, Kharasch ED, Skaar TC, Gaedigk A et al: Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther 2017, 102(1):37-44.

305. Dutch Guidelines. [https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf]

306. Swen JJ, Nijenhuis M, de Boer A, Grandia L, Maitland-van der Zee AH, Mulder H, Rongen GA, van Schaik RH, Schalekamp T, Touw DJ et al: Pharmacogenetics: from bench to byte--an update of guidelines. Clin Pharmacol Ther 2011, 89(5):662-673.

307. Dutch guidelines May 2020 update [https://api.pharmgkb.org/v1/download/file/attachment/DPWG_May_2020.pdf]

308. Ryu S, Park S, Lee JH, Kim YR, Na HS, Lim HS, Choi HY, Hwang IY, Lee JG, Park ZW et al: A Study on CYP2C19 and CYP2D6 Polymorphic Effects on Pharmacokinetics and Pharmacodynamics of Amitriptyline in Healthy Koreans. Clin Transl Sci 2017, 10(2):93-101.

309. Atasayar G, Eryilmaz IE, Karli N, Egeli U, Zarifoglu M, Cecener G, Taskapilioglu O, Tunca B, Yildirim O, Ak S et al: Association of MDR1, CYP2D6, and CYP2C19 gene polymorphisms with prophylactic migraine treatment response. J Neurol Sci 2016, 366:149-154.

310. de Vos A, van der Weide J, Loovers HM: Association between CYP2C19*17 and metabolism of amitriptyline, citalopram and clomipramine in Dutch hospitalized patients. Pharmacogenomics J 2011, 11(5):359-367.

311. Bijl MJ, Visser LE, Hofman A, Vulto AG, van Gelder T, Stricker BH, van Schaik RH: Influence of the CYP2D6*4 polymorphism on dose, switching and discontinuation of antidepressants. Br J Clin Pharmacol 2008, 65(4):558-564.

312. Steimer W, Zopf K, von Amelunxen S, Pfeiffer H, Bachofer J, Popp J, Messner B, Kissling W, Leucht S: Amitriptyline or not, that is the question: pharmacogenetic testing of CYP2D6 and CYP2C19 identifies patients with low or high risk for side effects in amitriptyline therapy. Clin Chem 2005, 51(2):376-385.

313. Ishigooka J, Iwashita S, Higashi K, Liew EL, Tadori Y: Pharmacokinetics and Safety of Brexpiprazole Following Multiple-Dose Administration to Japanese Patients With Schizophrenia. J Clin Pharmacol 2018, 58(1):74-80.

314. Kirchheiner J, Meineke I, Muller G, Roots I, Brockmoller J: Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers. Pharmacogenetics 2002, 12(7):571-580.

315. Fabbri C, Tansey KE, Perlis RH, Hauser J, Henigsberg N, Maier W, Mors O, Placentino A, Rietschel M, Souery D et al: Effect of cytochrome CYP2C19 metabolizing activity on antidepressant response and side effects: Meta-analysis of data from genome-wide association studies. Eur Neuropsychopharmacol 2018, 28(8):945-954.

316. Demirbugen Oz M, Uckun Z, Yuce-Artun N, Baskak B, Ozdemir H, Kizil Ozel T, Devrimci Ozguven H, Suzen HS: The relationship between the serotonin 2A receptor gene -1438A/G and 102T/C polymorphisms and citalopram/sertraline-induced nausea in major depressed patients. Hum Psychopharmacol 2018, 33(5):e2673.

317. Mrazek DA, Biernacka JM, O'Kane DJ, Black JL, Cunningham JM, Drews MS, Snyder KA, Stevens SR, Rush AJ, Weinshilboum RM: CYP2C19 variation and citalopram response. Pharmacogenet Genomics 2011, 21(1):1-9.

318. Kumar Y, Kung S, Shinozaki G: CYP2C19 variation, not citalopram dose nor serum level, is associated with QTc prolongation. J Psychopharmacol 2014, 28(12):1143-1148.

319. Chang M, Tybring G, Dahl ML, Lindh JD: Impact of cytochrome P450 2C19 polymorphisms on citalopram/escitalopram exposure: a systematic review and meta-analysis. Clin Pharmacokinet 2014, 53(9):801-811.

320. Shiroma PR, Drews MS, Geske JR, Mrazek DA: SLC6A4 polymorphisms and age of onset in late-life depression on treatment outcomes with citalopram: a Sequenced Treatment Alternatives to Relieve Depression (STAR*D) report. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry 2014, 22(11):1140-1148.

321. Rotberg B, Kronenberg S, Carmel M, Frisch A, Brent D, Zalsman G, Apter A, Weizman A: Additive effects of 5-HTTLPR (serotonin transporter) and tryptophan hydroxylase 2 G-703T gene polymorphisms on the clinical response to citalopram among children and adolescents with depression and anxiety disorders. J Child Adolesc Psychopharmacol 2013, 23(2):117-122.

322. Illi A, Poutanen O, Setala-Soikkeli E, Kampman O, Viikki M, Huhtala H, Mononen N, Haraldsson S, Koivisto PA, Leinonen E et al: Is 5-HTTLPR linked to the response of selective serotonin reuptake inhibitors in MDD? Eur Arch Psychiatry Clin Neurosci 2011, 261(2):95-102.

323. Min W, Li T, Ma X, Li Z, Yu T, Gao D, Zhang B, Yun Y, Sun X: Monoamine transporter gene polymorphisms affect susceptibility to depression and predict antidepressant response. Psychopharmacology (Berl) 2009, 205(3):409-417.

324. Mrazek DA, Rush AJ, Biernacka JM, O'Kane DJ, Cunningham JM, Wieben ED, Schaid DJ, Drews MS, Courson VL, Snyder KA et al: SLC6A4 variation and citalopram response. Am J Med Genet B Neuropsychiatr Genet 2009, 150B(3):341-351.

325. Hu XZ, Rush AJ, Charney D, Wilson AF, Sorant AJ, Papanicolaou GJ, Fava M, Trivedi MH, Wisniewski SR, Laje G et al: Association between a functional serotonin transporter promoter polymorphism and citalopram treatment in adult outpatients with major depression. Arch Gen Psychiatry 2007, 64(7):783-792.

326. Arias B, Catalan R, Gasto C, Gutierrez B, Fananas L: 5-HTTLPR polymorphism of the serotonin transporter gene predicts non-remission in major depression patients treated with citalopram in a 12-weeks follow up study. J Clin Psychopharmacol 2003, 23(6):563-567.

327. Poland RE, Lesser IM, Wan YJ, Gertsik L, Yao J, Raffel LJ, Lin KM, Myers HF: Response to citalopram is not associated with SLC6A4 genotype in African-Americans and Caucasians with major depression. Life Sci 2013, 92(20-21):967-970.

328. Veldic M, Ahmed AT, Blacker CJ, Geske JR, Biernacka JM, Borreggine KL, Moore KM, Prieto ML, Vande Voort JL, Croarkin PE et al: Cytochrome P450 2C19 Poor Metabolizer Phenotype in Treatment Resistant Depression: Treatment and Diagnostic Implications. Front Pharmacol 2019, 10:83.

329. Fischer AG, Endrass T, Goebel I, Reuter M, Montag C, Kubisch C, Ullsperger M: Interactive effects of citalopram and serotonin transporter genotype on neural correlates of response inhibition and attentional orienting. Neuroimage 2015, 116:59-67.

330. Outhred T, Das P, Dobson-Stone C, Felmingham KL, Bryant RA, Nathan PJ, Malhi GS, Kemp AH: Impact of 5-HTTLPR on SSRI serotonin transporter blockade during emotion regulation: A preliminary fMRI study. J Affect Disord 2016, 196:11-19.

331. Tatham EL, Hall GB, Clark D, Foster J, Ramasubbu R: The 5-HTTLPR and BDNF polymorphisms moderate the association between uncinate fasciculus connectivity and antidepressants treatment response in major depression. Eur Arch Psychiatry Clin Neurosci 2017, 267(2):135-147.

332. Lee EJ, Oh MS, Kim JS, Chang DI, Park JH, Cha JK, Heo JH, Sohn SI, Kim DE, Kim HY et al: Serotonin transporter gene polymorphisms may be associated with poststroke neurological recovery after escitalopram use. J Neurol Neurosurg Psychiatry 2018, 89(3):271-276.

333. Basu A, Chadda RK, Sood M, Kaur H, Kukreti R: Association of serotonin transporter (SLC6A4) and receptor (5HTR1A, 5HTR2A) polymorphisms with response to treatment with escitalopram in patients with major depressive disorder: A preliminary study. Indian J Med Res 2015, 142(1):40-45.

334. Serretti A, Kato M, De Ronchi D, Kinoshita T: Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients. Mol Psychiatry 2007, 12(3):247-257.

335. Kato M, Serretti A: Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder. Mol Psychiatry 2010, 15(5):473-500.

336. Porcelli S, Fabbri C, Serretti A: Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with antidepressant efficacy. Eur Neuropsychopharmacol 2012, 22(4):239-258.

337. Kawaguchi DM, Glatt SJ: GRIK4 polymorphism and its association with antidepressant response in depressed patients: a meta-analysis. Pharmacogenomics 2014, 15(11):1451-1459.

338. Pu M, Zhang Z, Xu Z, Shi Y, Geng L, Yuan Y, Zhang X, Reynolds GP: Influence of genetic polymorphisms in the glutamatergic and GABAergic systems and their interactions with environmental stressors on antidepressant response. Pharmacogenomics 2013, 14(3):277-288.

339. Horstmann S, Lucae S, Menke A, Hennings JM, Ising M, Roeske D, Muller-Myhsok B, Holsboer F, Binder EB: Polymorphisms in GRIK4, HTR2A, and FKBP5 show interactive effects in predicting remission to antidepressant treatment. Neuropsychopharmacology 2010, 35(3):727-740.

340. Paddock S, Laje G, Charney D, Rush AJ, Wilson AF, Sorant AJ, Lipsky R, Wisniewski SR, Manji H, McMahon FJ: Association of GRIK4 with outcome of antidepressant treatment in the STAR*D cohort. The American journal of psychiatry 2007, 164(8):1181-1188.

341. Zou YF, Wang F, Feng XL, Li WF, Tao JH, Pan FM, Huang F, Su H: Meta-analysis of FKBP5 gene polymorphisms association with treatment response in patients with mood disorders. Neurosci Lett 2010, 484(1):56-61.

342. Lekman M, Laje G, Charney D, Rush AJ, Wilson AF, Sorant AJ, Lipsky R, Wisniewski SR, Manji H, McMahon FJ et al: The FKBP5-gene in depression and treatment response--an association study in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Cohort. Biol Psychiatry 2008, 63(12):1103-1110.

343. Binder EB, Salyakina D, Lichtner P, Wochnik GM, Ising M, Putz B, Papiol S, Seaman S, Lucae S, Kohli MA et al: Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment. Nat Genet 2004, 36(12):1319-1325.

344. Niitsu T, Fabbri C, Bentini F, Serretti A: Pharmacogenetics in major depression: a comprehensive meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry 2013, 45:183-194.

345. Noro M, Antonijevic I, Forray C, Kasper S, Kocabas NA, Lecrubier Y, Linotte S, Mendlewicz J, Montgomery S, Snyder L et al: 5HT1A and 5HT2A receptor genes in treatment response phenotypes in major depressive disorder. Int Clin Psychopharmacol 2010, 25(4):228-231.

346. Viikki M, Huuhka K, Leinonen E, Illi A, Setala-Soikkeli E, Huuhka M, Mononen N, Lehtimaki T, Kampman O: Interaction between two HTR2A polymorphisms and gender is associated with treatment response in MDD. Neurosci Lett 2011, 501(1):20-24.

347. Kishi T, Yoshimura R, Kitajima T, Okochi T, Okumura T, Tsunoka T, Yamanouchi Y, Kinoshita Y, Kawashima K, Naitoh H et al: HTR2A is associated with SSRI response in major depressive disorder in a Japanese cohort. Neuromolecular Med 2010, 12(3):237-242.

348. Peters EJ, Slager SL, Jenkins GD, Reinalda MS, Garriock HA, Shyn SI, Kraft JB, McGrath PJ, Hamilton SP: Resequencing of serotonin-related genes and association of tagging SNPs to citalopram response. Pharmacogenet Genomics 2009, 19(1):1-10.

349. McMahon FJ, Buervenich S, Charney D, Lipsky R, Rush AJ, Wilson AF, Sorant AJ, Papanicolaou GJ, Laje G, Fava M et al: Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. Am J Hum Genet 2006, 78(5):804-814.

350. GENDEP Investigators; MARS Investigators SDI: Common genetic variation and antidepressant efficacy in major depressive disorder: a meta-analysis of three genome-wide pharmacogenetic studies. Am J Psychiatry 2013, 170(2):207-217.

351. Hodgson K, Tansey K, Dernovsek MZ, Hauser J, Henigsberg N, Maier W, Mors O, Placentino A, Rietschel M, Souery D et al: Genetic differences in cytochrome P450 enzymes and antidepressant treatment response. J Psychopharmacol 2014, 28(2):133-141.

352. Waade RB, Hermann M, Moe HL, Molden E: Impact of age on serum concentrations of venlafaxine and escitalopram in different CYP2D6 and CYP2C19 genotype subgroups. Eur J Clin Pharmacol 2014, 70(8):933-940.

353. Jukic MM, Haslemo T, Molden E, Ingelman-Sundberg M: Impact of CYP2C19 Genotype on Escitalopram Exposure and Therapeutic Failure: A Retrospective Study Based on 2,087 Patients. Am J Psychiatry 2018, 175(5):463-470.

354. Aldrich SL, Poweleit EA, Prows CA, Martin LJ, Strawn JR, Ramsey LB: Influence of CYP2C19 Metabolizer Status on Escitalopram/Citalopram Tolerability and Response in Youth With Anxiety and Depressive Disorders. Front Pharmacol 2019, 10:99.

355. Ng C, Sarris J, Singh A, Bousman C, Byron K, Peh LH, Smith DJ, Tan CH, Schweitzer I: Pharmacogenetic polymorphisms and response to escitalopram and venlafaxine over 8 weeks in major depression. Hum Psychopharmacol 2013, 28(5):516-522.

356. Strohmaier J, Wust S, Uher R, Henigsberg N, Mors O, Hauser J, Souery D, Zobel A, Dernovsek MZ, Streit F et al: Sexual dysfunction during treatment with serotonergic and noradrenergic antidepressants: clinical description and the role of the 5-HTTLPR. World J Biol Psychiatry 2011, 12(7):528-538.

357. Keers R, Uher R, Huezo-Diaz P, Smith R, Jaffee S, Rietschel M, Henigsberg N, Kozel D, Mors O, Maier W et al: Interaction between serotonin transporter gene variants and life events predicts response to antidepressants in the GENDEP project. Pharmacogenomics J 2011, 11(2):138-145.

358. Maron E, Tammiste A, Kallassalu K, Eller T, Vasar V, Nutt DJ, Metspalu A: Serotonin transporter promoter region polymorphisms do not influence treatment response to escitalopram in patients with major depression. Eur Neuropsychopharmacol 2009, 19(6):451-456.

359. Alexopoulos GS, Murphy CF, Gunning-Dixon FM, Glatt CE, Latoussakis V, Kelly RE, Jr., Kanellopoulos D, Klimstra S, Lim KO, Young RC et al: Serotonin transporter polymorphisms, microstructural white matter abnormalities and remission of geriatric depression. J Affect Disord 2009, 119(1-3):132-141.

360. Huezo-Diaz P, Uher R, Smith R, Rietschel M, Henigsberg N, Marusic A, Mors O, Maier W, Hauser J, Souery D et al: Moderation of antidepressant response by the serotonin transporter gene. Br J Psychiatry 2009, 195(1):30-38.

361. Poweleit EA, Aldrich SL, Martin LJ, Hahn D, Strawn JR, Ramsey LB: Pharmacogenetics of Sertraline Tolerability and Response in Pediatric Anxiety and Depressive Disorders. J Child Adolesc Psychopharmacol 2019, 29(5):348-361.

362. Brandl EJ, Tiwari AK, Zhou X, Deluce J, Kennedy JL, Muller DJ, Richter MA: Influence of CYP2D6 and CYP2C19 gene variants on antidepressant response in obsessive-compulsive disorder. Pharmacogenomics J 2014, 14(2):176-181.

363. Rudberg I, Hermann M, Refsum H, Molden E: Serum concentrations of sertraline and N-desmethyl sertraline in relation to CYP2C19 genotype in psychiatric patients. Eur J Clin Pharmacol 2008, 64(12):1181-1188.

364. Grasmader K, Verwohlt PL, Rietschel M, Dragicevic A, Muller M, Hiemke C, Freymann N, Zobel A, Maier W, Rao ML: Impact of polymorphisms of cytochrome-P450 isoenzymes 2C9, 2C19 and 2D6 on plasma concentrations and clinical effects of antidepressants in a naturalistic clinical setting. Eur J Clin Pharmacol 2004, 60(5):329-336.

365. Wang JH, Liu ZQ, Wang W, Chen XP, Shu Y, He N, Zhou HH: Pharmacokinetics of sertraline in relation to genetic polymorphism of CYP2C19. Clin Pharmacol Ther 2001, 70(1):42-47.

366. Zastrozhin MS, Grishina EA, Denisenko NP, Skryabin VY, Markov DD, Savchenko LM, Bryun EA, Sychev DA: Effects of CYP2D6 genetic polymorphisms on the efficacy and safety of fluvoxamine in patients with depressive disorder and comorbid alcohol use disorder. Pharmgenomics Pers Med 2018, 11:113-119.

367. Muller DJ, Brandl EJ, Hwang R, Tiwari AK, Sturgess JE, Zai CC, Lieberman JA, Kennedy JL, Richter MA: The AmpliChip(R) CYP450 test and response to treatment in schizophrenia and obsessive compulsive disorder: a pilot study and focus on cases with abnormal CYP2D6 drug metabolism. Genet Test Mol Biomarkers 2012, 16(8):897-903.

368. Suzuki Y, Sugai T, Fukui N, Watanabe J, Ono S, Inoue Y, Ozdemir V, Someya T: CYP2D6 genotype and smoking influence fluvoxamine steady-state concentration in Japanese psychiatric patients: lessons for genotype-phenotype association study design in translational pharmacogenetics. J Psychopharmacol 2011, 25(7):908-914.

369. Katoh Y, Uchida S, Kawai M, Takei N, Mori N, Kawakami J, Kagawa Y, Yamada S, Namiki N, Hashimoto H: Effects of cigarette smoking and cytochrome P450 2D6 genotype on fluvoxamine concentration in plasma of Japanese patients. Biol Pharm Bull 2010, 33(2):285-288.

370. Watanabe J, Suzuki Y, Fukui N, Sugai T, Ono S, Inoue Y, Someya T: Dose-dependent effect of the CYP2D6 genotype on the steady-state fluvoxamine concentration. Ther Drug Monit 2008, 30(6):705-708.

371. Suzuki Y, Sawamura K, Someya T: Polymorphisms in the 5-hydroxytryptamine 2A receptor and CytochromeP4502D6 genes synergistically predict fluvoxamine-induced side effects in japanese depressed patients. Neuropsychopharmacology 2006, 31(4):825-831.

372. Kawanishi C, Lundgren S, Agren H, Bertilsson L: Increased incidence of CYP2D6 gene duplication in patients with persistent mood disorders: ultrarapid metabolism of antidepressants as a cause of nonresponse. A pilot study. Eur J Clin Pharmacol 2004, 59(11):803-807.

373. Gerstenberg G, Aoshima T, Fukasawa T, Yoshida K, Takahashi H, Higuchi H, Murata Y, Shimoyama R, Ohkubo T, Shimizu T et al: Effects of the CYP 2D6 genotype and cigarette smoking on the steady-state plasma concentrations of fluvoxamine and its major metabolite fluvoxamino acid in Japanese depressed patients. Ther Drug Monit 2003, 25(4):463-468.

374. Gerstenberg G, Aoshima T, Fukasawa T, Yoshida K, Takahashi H, Higuchi H, Murata Y, Shimoyama R, Ohkubo T, Shimizu T et al: Relationship between clinical effects of fluvoxamine and the steady-state plasma concentrations of fluvoxamine and its major metabolite fluvoxamino acid in Japanese depressed patients. Psychopharmacology (Berl) 2003, 167(4):443-448.

375. Ohara K, Tanabu S, Ishibashi K, Ikemoto K, Yoshida K, Shibuya H: CYP2D6*10 alleles do not determine plasma fluvoxamine concentration/dose ratio in Japanese subjects. European journal of clinical pharmacology 2003, 58(10):659-661.

376. Spigset O, Axelsson S, Norstrom A, Hagg S, Dahlqvist R: The major fluvoxamine metabolite in urine is formed by CYP2D6. Eur J Clin Pharmacol 2001, 57(9):653-658.

377. Hartter S, Grozinger M, Weigmann H, Roschke J, Hiemke C: Increased bioavailability of oral melatonin after fluvoxamine coadministration. Clin Pharmacol Ther 2000, 67(1):1-6.

378. Nishimura M, Ueda M, Saruwatari J, Nakashima H, Ogusu N, Aoki A, Tsuchimine S, Matsuda K, Iwashita K, Ono T et al: Influence of the cytochrome P450 2D6 *10/*10 genotype on the pharmacokinetics of paroxetine in Japanese patients with major depressive disorder: a population pharmacokinetic analysis. Pharmacogenet Genomics 2016, 26(9):403-413.

379. Ishiguro S, Watanabe T, Ueda M, Saeki Y, Hayashi Y, Akiyama K, Saito A, Kato K, Inoue Y, Shimoda K: Determinants of pharmacodynamic trajectory of the therapeutic response to paroxetine in Japanese patients with panic disorder. Eur J Clin Pharmacol 2011, 67(12):1213-1221.

380. Yevtushenko OO, Oros MM, Reynolds GP: Early response to selective serotonin reuptake inhibitors in panic disorder is associated with a functional 5-HT1A receptor gene polymorphism. J Affect Disord 2010, 123(1-3):308-311.

381. Illi A, Setala-Soikkeli E, Viikki M, Poutanen O, Huhtala H, Mononen N, Lehtimaki T, Leinonen E, Kampman O: 5-HTR1A, 5-HTR2A, 5-HTR6, TPH1 and TPH2 polymorphisms and major depression. Neuroreport 2009, 20(12):1125-1128.

382. Haslemo T, Eliasson E, Jukic MM, Ingelman-Sundberg M, Molden E: Significantly lower CYP2D6 metabolism measured as the O/N-desmethylvenlafaxine metabolic ratio in carriers of CYP2D6*41 versus CYP2D6*9 or CYP2D6*10: a study on therapeutic drug monitoring data from 1003 genotyped Scandinavian patients. Br J Clin Pharmacol 2019, 85(1):194-201.

383. Lin XQ, Wang P, Cai WK, Xu GL, Yang M, Zhou MD, Sun M, He F, He GH: The Associations Between CYP2D6 Metabolizer Status and Pharmacokinetics and Clinical Outcomes of Venlafaxine: A Systematic Review and Meta-Analysis. Pharmacopsychiatry 2018.

384. Lobello KW, Preskorn SH, Guico-Pabia CJ, Jiang Q, Paul J, Nichols AI, Patroneva A, Ninan PT: Cytochrome P450 2D6 phenotype predicts antidepressant efficacy of venlafaxine: a secondary analysis of 4 studies in major depressive disorder. J Clin Psychiatry 2010, 71(11):1482-1487.

385. McAlpine DE, O'Kane DJ, Black JL, Mrazek DA: Cytochrome P450 2D6 genotype variation and venlafaxine dosage. Mayo Clin Proc 2007, 82(9):1065-1068.

386. Lessard E, Yessine MA, Hamelin BA, O'Hara G, LeBlanc J, Turgeon J: Influence of CYP2D6 activity on the disposition and cardiovascular toxicity of the antidepressant agent venlafaxine in humans. Pharmacogenetics 1999, 9(4):435-443.

387. Van Nieuwerburgh FC, Denys DA, Westenberg HG, Deforce DL: Response to serotonin reuptake inhibitors in OCD is not influenced by common CYP2D6 polymorphisms. Int J Psychiatry Clin Pract 2009, 13(1):345-348.

388. Hermann M, Hendset M, Fosaas K, Hjerpset M, Refsum H: Serum concentrations of venlafaxine and its metabolites O-desmethylvenlafaxine and N-desmethylvenlafaxine in heterozygous carriers of the CYP2D6*3, *4 or *5 allele. European journal of clinical pharmacology 2008, 64(5):483-487.

389. Shams ME, Arneth B, Hiemke C, Dragicevic A, Muller MJ, Kaiser R, Lackner K, Hartter S: CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine. J Clin Pharm Ther 2006, 31(5):493-502.

390. van der Weide J, van Baalen-Benedek EH, Kootstra-Ros JE: Metabolic ratios of psychotropics as indication of cytochrome P450 2D6/2C19 genotype. Ther Drug Monit 2005, 27(4):478-483.

391. Eap CB, Lessard E, Baumann P, Brawand-Amey M, Yessine MA, O'Hara G, Turgeon J: Role of CYP2D6 in the stereoselective disposition of venlafaxine in humans. Pharmacogenetics 2003, 13(1):39-47.

392. Fukuda T, Nishida Y, Zhou Q, Yamamoto I, Kondo S, Azuma J: The impact of the CYP2D6 and CYP2C19 genotypes on venlafaxine pharmacokinetics in a Japanese population. Eur J Clin Pharmacol 2000, 56(2):175-180.

393. Veefkind AH, Haffmans PM, Hoencamp E: Venlafaxine serum levels and CYP2D6 genotype. Ther Drug Monit 2000, 22(2):202-208.

394. Fukuda T, Yamamoto I, Nishida Y, Zhou Q, Ohno M, Takada K, Azuma J: Effect of the CYP2D6*10 genotype on venlafaxine pharmacokinetics in healthy adult volunteers. British journal of clinical pharmacology 1999, 47(4):450-453.

395. Preskorn S, Patroneva A, Silman H, Jiang Q, Isler JA, Burczynski ME, Ahmed S, Paul J, Nichols AI: Comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine in extensive and poor cytochrome P450 2D6 metabolizers. J Clin Psychopharmacol 2009, 29(1):39-43.

396. Jaquenoud Sirot E, Harenberg S, Vandel P, Lima CA, Perrenoud P, Kemmerling K, Zullino DF, Hilleret H, Crettol S, Jonzier-Perey M et al: Multicenter study on the clinical effectiveness, pharmacokinetics, and pharmacogenetics of mirtazapine in depression. J Clin Psychopharmacol 2012, 32(5):622-629.

397. Borobia AM, Novalbos J, Guerra-Lopez P, Lopez-Rodriguez R, Tabares B, Rodriguez V, Abad-Santos F, Carcas AJ: Influence of sex and CYP2D6 genotype on mirtazapine disposition, evaluated in Spanish healthy volunteers. Pharmacol Res 2009, 59(6):393-398.

398. Lind AB, Reis M, Bengtsson F, Jonzier-Perey M, Powell Golay K, Ahlner J, Baumann P, Dahl ML: Steady-state concentrations of mirtazapine, N-desmethylmirtazapine, 8-hydroxymirtazapine and their enantiomers in relation to cytochrome P450 2D6 genotype, age and smoking behaviour. Clin Pharmacokinet 2009, 48(1):63-70.

399. Brockmoller J, Meineke I, Kirchheiner J: Pharmacokinetics of mirtazapine: enantioselective effects of the CYP2D6 ultra rapid metabolizer genotype and correlation with adverse effects. Clin Pharmacol Ther 2007, 81(5):699-707.

400. Kirchheiner J, Henckel HB, Meineke I, Roots I, Brockmoller J: Impact of the CYP2D6 ultrarapid metabolizer genotype on mirtazapine pharmacokinetics and adverse events in healthy volunteers. J Clin Psychopharmacol 2004, 24(6):647-652.

401. Murphy GM, Jr., Kremer C, Rodrigues HE, Schatzberg AF: Pharmacogenetics of antidepressant medication intolerance. Am J Psychiatry 2003, 160(10):1830-1835.

402. Saiz-Rodriguez M, Belmonte C, Derqui-Fernandez N, Cabaleiro T, Roman M, Ochoa D, Talegon M, Ovejero-Benito MC, Abad-Santos F: Pharmacogenetics of trazodone in healthy volunteers: association with pharmacokinetics, pharmacodynamics and safety. Pharmacogenomics 2017, 18(16):1491-1502.

403. Saiz-Rodriguez M, Belmonte C, Roman M, Ochoa D, Jiang-Zheng C, Koller D, Mejia G, Zubiaur P, Wojnicz A, Abad-Santos F: Effect of ABCB1 C3435T Polymorphism on Pharmacokinetics of Antipsychotics and Antidepressants. Basic Clin Pharmacol Toxicol 2018, 123(4):474-485.

404. Pharmacogenomic Testing for Psychotropic Medication Selection: A Systematic Review of the Assurex GeneSight Psychotropic Test. Ont Health Technol Assess Ser 2017, 17(4):1-39.

405. Areberg J, Petersen KB, Chen G, Naik H: Population pharmacokinetic meta-analysis of vortioxetine in healthy individuals. Basic Clin Pharmacol Toxicol 2014, 115(6):552-559.

406. David SP, Strong DR, Leventhal AM, Lancaster MA, McGeary JE, Munafo MR, Bergen AW, Swan GE, Benowitz NL, Tyndale RF et al: Influence of a dopamine pathway additive genetic efficacy score on smoking cessation: results from two randomized clinical trials of bupropion. Addiction 2013, 108(12):2202-2211.

407. Breitling LP, Twardella D, Hoffmann MM, Witt SH, Treutlein J, Brenner H: Prospective association of dopamine-related polymorphisms with smoking cessation in general care. Pharmacogenomics 2010, 11(4):527-536.

408. Lerman C, Shields PG, Wileyto EP, Audrain J, Hawk LH, Jr., Pinto A, Kucharski S, Krishnan S, Niaura R, Epstein LH: Effects of dopamine transporter and receptor polymorphisms on smoking cessation in a bupropion clinical trial. Health Psychol 2003, 22(5):541-548.

409. Tomaz PR, Santos JR, Issa JS, Abe TO, Gaya PV, Krieger JE, Pereira AC, Santos PC: CYP2B6 rs2279343 polymorphism is associated with smoking cessation success in bupropion therapy. Eur J Clin Pharmacol 2015, 71(9):1067-1073.

410. Hubacek JA, Pankova A, Stepankova L, Zvolska K, Adamkova V, Lanska V, Kralikova E: SNPs within CHRNA5-A3-B4 and CYP2A6/B6 are associated with smoking dependence but not with tobacco dependence treatment outcomes in the Czech population. Gene 2017, 606:35-38.

411. Lee AM, Jepson C, Hoffmann E, Epstein L, Hawk LW, Lerman C, Tyndale RF: CYP2B6 genotype alters abstinence rates in a bupropion smoking cessation trial. Biol Psychiatry 2007, 62(6):635-641.

412. Lerman C, Shields PG, Wileyto EP, Audrain J, Pinto A, Hawk L, Krishnan S, Niaura R, Epstein L: Pharmacogenetic investigation of smoking cessation treatment. Pharmacogenetics 2002, 12(8):627-634.

413. David SP, Strong DR, Munafo MR, Brown RA, Lloyd-Richardson EE, Wileyto PE, Evins EA, Shields PG, Lerman C, Niaura R: Bupropion efficacy for smoking cessation is influenced by the DRD2 Taq1A polymorphism: analysis of pooled data from two clinical trials. Nicotine Tob Res 2007, 9(12):1251-1257.

414. David SP, Brown RA, Papandonatos GD, Kahler CW, Lloyd-Richardson EE, Munafo MR, Shields PG, Lerman C, Strong D, McCaffery J et al: Pharmacogenetic clinical trial of sustained-release bupropion for smoking cessation. Nicotine Tob Res 2007, 9(8):821-833.

415. Swan GE, Valdes AM, Ring HZ, Khroyan TV, Jack LM, Ton CC, Curry SJ, McAfee T: Dopamine receptor DRD2 genotype and smoking cessation outcome following treatment with bupropion SR. Pharmacogenomics J 2005, 5(1):21-29.

416. Zhang JP, Lencz T, Zhang RX, Nitta M, Maayan L, John M, Robinson DG, Fleischhacker WW, Kahn RS, Ophoff RA et al: Pharmacogenetic Associations of Antipsychotic Drug-Related Weight Gain: A Systematic Review and Meta-analysis. Schizophr Bull 2016, 42(6):1418-1437.

417. Zhang JP, Lencz T, Malhotra AK: D2 receptor genetic variation and clinical response to antipsychotic drug treatment: a meta-analysis. Am J Psychiatry 2010, 167(7):763-772.

418. Alenius M, Wadelius M, Dahl ML, Hartvig P, Lindstrom L, Hammarlund-Udenaes M: Gene polymorphism influencing treatment response in psychotic patients in a naturalistic setting. J Psychiatr Res 2008, 42(11):884-893.

419. Bakker PR, van Harten PN, van Os J: Antipsychotic-induced tardive dyskinesia and polymorphic variations in COMT, DRD2, CYP1A2 and MnSOD genes: a meta-analysis of pharmacogenetic interactions. Mol Psychiatry 2008, 13(5):544-556.

420. Zai CC, De Luca V, Hwang RW, Voineskos A, Muller DJ, Remington G, Kennedy JL: Meta-analysis of two dopamine D2 receptor gene polymorphisms with tardive dyskinesia in schizophrenia patients. Mol Psychiatry 2007, 12(9):794-795.

421. Muller DJ, Zai CC, Sicard M, Remington E, Souza RP, Tiwari AK, Hwang R, Likhodi O, Shaikh S, Freeman N et al: Systematic analysis of dopamine receptor genes (DRD1-DRD5) in antipsychotic-induced weight gain. Pharmacogenomics J 2012, 12(2):156-164.

422. Ohara K, Nagai M, Tani K, Nakamura Y, Ino A, Ohara K: Functional polymorphism of −141C Ins/Del in the dopamine D2 receptor gene promoter and schizophrenia. Psychiatry Research 1998, 81(2):117-123.

423. Zhang J-P, Lencz T, Malhotra AK: D2 Receptor Genetic Variation and Clinical Response to Antipsychotic Drug Treatment: A Meta-Analysis. American Journal of Psychiatry 2010, 167(7):763-772.

424. Mulder H, Cohen D, Scheffer H, Gispen-de Wied C, Arends J, Wilmink FW, Franke B, Egberts AC: HTR2C gene polymorphisms and the metabolic syndrome in patients with schizophrenia: a replication study. J Clin Psychopharmacol 2009, 29(1):16-20.

425. Mulder H, Franke B, van der-Beek van der AA, Arends J, Wilmink FW, Scheffer H, Egberts AC: The association between HTR2C gene polymorphisms and the metabolic syndrome in patients with schizophrenia. J Clin Psychopharmacol 2007, 27(4):338-343.

426. Risselada AJ, Mulder H, Heerdink ER, Gonera RK, Egberts TC: Association between the HTR2C rs1414334 and ADRA2A 1291 C/G polymorphisms and lipid levels in obese patients. In: Genetic determinants for metabolic abnormalities. edn.; 2012: 107.

427. Czerwensky F, Leucht S, Steimer W: MC4R rs489693: a clinical risk factor for second generation antipsychotic-related weight gain? Int J Neuropsychopharmacol 2013, 16(9):2103-2109.

428. Malhotra AK, Correll CU, Chowdhury NI, Muller DJ, Gregersen PK, Lee AT, Tiwari AK, Kane JM, Fleischhacker WW, Kahn RS et al: Association between common variants near the melanocortin 4 receptor gene and severe antipsychotic drug-induced weight gain. Arch Gen Psychiatry 2012, 69(9):904-912.

429. Ma X, Maimaitirexiati T, Zhang R, Gui X, Zhang W, Xu G, Hu G: HTR2C polymorphisms, olanzapine-induced weight gain and antipsychotic-induced metabolic syndrome in schizophrenia patients: a meta-analysis. Int J Psychiatry Clin Pract 2014, 18(4):229-242.

430. Hiemke C, Baumann P, Bergemann N, Conca A, Dietmaier O, Egberts K, Fric M, Gerlach M, Greiner C, Grunder G et al: AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update 2011. Pharmacopsychiatry 2011, 44(6):195-235.

431. Xing Q, Qian X, Li H, Wong S, Wu S, Feng G, Duan S, Xu M, Gao R, Qin W: The relationship between the therapeutic response to risperidone and the dopamine D2 receptor polymorphism in Chinese schizophrenia patients. International Journal of Neuropsychopharmacology 2007, 10(5):631-637.

432. Ikeda M, Yamanouchi Y, Kinoshita Y, Kitajima T, Yoshimura R, Hashimoto S, O'Donovan MC, Nakamura J, Ozaki N, Iwata N: Variants of dopamine and serotonin candidate genes as predictors of response to risperidone treatment in first-episode schizophrenia. 2008.

433. Lencz T, Robinson DG, Xu K, Ekholm J, Sevy S, Gunduz-Bruce H, Woerner MG, Kane JM, Goldman D, Malhotra AK: DRD2 promoter region variation as a predictor of sustained response to antipsychotic medication in first-episode schizophrenia patients. American Journal of Psychiatry 2006, 163(3):529-531.
DPWG. Dutch Guidelines. https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf. Published 2019. Accessed October 22, 2019.